

Objection Deadline: July 21, 2020 @ 12:00 p.m. (ET)

UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK

In re:

PURDUE PHARMA L.P., *et al.*,¹

Debtors.

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**NINTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR
ALLOWANCE OF COMPENSATION FOR SERVICES
RENDERED AND FOR REIMBURSEMENT OF EXPENSES
FOR THE PERIOD MAY 1, 2020 THROUGH MAY 31, 2020**

Name of Applicant:	ALIXPARTNERS, LLP	
Applicant's Role in Case:	Financial Advisor to the Chapter 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019	
Time period covered by this statement:	Beginning of Period	End of Period
	May 1, 2020	May 31, 2020
Summary of Total Fees and Expenses Requested:		
Total fees requested in this statement:	\$1,138,233.60 (80% of \$1,422,792.00)	
Total expenses requested in this statement:	\$10,111.83	
Total fees and expenses requested in this statement:	\$1,148,345.43	
This is a(n): <input checked="" type="checkbox"/> Monthly Application <input type="checkbox"/> Interim Application <input type="checkbox"/> Final Application		

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrum Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL
FOR THE PERIOD MAY 1, 2020 THROUGH MAY 31, 2020**

PROFESSIONAL	TITLE	RATE	HOURS	FEES
Lisa Donahue	Managing Director	\$1,195	36.0	\$ 43,020.00
Richard Collura	Managing Director	\$1,090	102.3	111,507.00
Jesse DelConte	Director	\$950	149.1	141,645.00
Kevin M McCafferty	Director	\$950	146.7	139,365.00
Mark F Rule	Director	\$910	170.2	154,882.00
Michael Hartley	Director	\$840	5.5	4,620.00
Gabe J Koch	Director	\$840	189.5	159,180.00
Elizabeth S Kardos	Director	\$710	0.2	142.00
Ryan D Sublett	Senior Vice President	\$735	110.7	81,364.50
Isabel Arana de Uriate	Senior Vice President	\$690	95.4	65,826.00
Jon D Hecht	Senior Vice President	\$690	124.5	85,905.00
Sam J Canniff	Senior Vice President	\$645	144.7	93,331.50
Kristina Galbraith	Senior Vice President	\$645	1.8	1,161.00
Kyoko Shibuya	Senior Vice President	\$645	14.4	9,288.00
Fernando O Silva	Senior Vice President	\$645	105.9	68,305.50
Kaitlyn A Sundt	Senior Vice President	\$510	2.7	1,377.00
Laurie C Verry	Senior Vice President	\$510	0.3	153.00
Andrew D DePalma	Vice President	\$515	167.7	86,365.50
Hart Ku	Vice President	\$515	0.2	103.00
Sam K Lemack	Vice President	\$515	173.7	89,455.50
Nate A Simon	Vice President	\$515	117.5	60,512.50
Tammy Brewer	Vice President	\$450	6.1	2,745.00
Brooke F Filler	Vice President	\$445	0.1	44.50
Melanie McCabe	Vice President	\$415	45.7	18,965.50
Roy Ellis Ochoa	Consultant	\$420	8.4	3,528.00
Total Professional Hours and Fees			1,919.3	\$ 1,422,792.00
Less 50% Travel Fees				-
Subtotal				\$ 1,422,792.00
Less 20% Holdback				(284,558.40)
Invoice Total				\$ 1,138,233.60
			Average Billing Rate	\$ 741.31

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY MATTER CATEGORY
FOR THE PERIOD MAY 1, 2020 THROUGH MAY 31, 2020**

CODE	MATTER CATEGORY	HOURS	FEES
101	Chapter 11 Process/Case Management	71.9	\$ 61,662.00
103	Cash Management	215.0	120,761.50
104	Communication with Interested Parties	160.6	96,373.50
105	U.S. Trustee / Court Reporting Requirements	18.9	11,406.50
106	Business Analysis & Operations	705.6	570,884.50
108	Executory Contracts	0.5	475.00
110	Special Projects	1.8	1,161.00
112	Retention and Engagement Administration	1.6	1,299.50
113	Fee Statements and Fee Applications	63.4	31,179.00
114	Court Hearings	5.2	5,002.50
115	Forensic Analysis	674.8	522,587.00
		<u>1,919.3</u>	<u>\$ 1,422,792.00</u>
	Average Billing Rate		<u>\$ 741.31</u>

ALIXPARTNERS, LLP

**SUMMARY OF EXPENSES
FOR THE PERIOD MAY 1, 2020 THROUGH MAY 31, 2020**

EXPENSE CATEGORY	EXPENSE
Airfare	\$ (5.60)
Other	10,117.43
Total	<u>\$ 10,111.83</u>

AlixPartners, LLP (“AlixPartners”), as Financial Advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Ninth Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period May 1, 2020 through May 31, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* (Docket No. 528) and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$1,422,792.00, without prejudice to a final allowance of compensation, plus reimbursement of actual and necessary out-of-pocket expenses incurred in the amount of \$10,111.83, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$1,138,233.60 (80% of \$1,422,792.00) and expenses in the amount of \$10,111.83, for a total amount of \$1,148,345.43.

Dated: July 7, 2020

ALIXPARTNERS, LLP
909 Third Avenue, 28th Floor
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue
Managing Director

Exhibit A

Alix Partners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/01/20	LJD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	MFR	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	SKL	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	SJC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	IA	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	NAS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	GJK	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	JDH	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/01/20	RC	update call. Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	JD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/01/20	JD	Call with R. Aleali (Purdue) re: post hearing catch up.	0.40
05/01/20	ADD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, M. Rule, N. Simon, (all AlixPartners) re: Weekly team update call.	0.80
05/04/20	JD	Review previous fee statements and respond to questions from J. Lowne (Purdue).	0.80
05/04/20	JD	Call with R. Aleali (Purdue) re: update on business plan call, due diligence update and go forward planning.	1.20
05/04/20	LJD	Update call with PJT.	0.40
05/04/20	LJD	Debrief call with J. Dub el (Purdue board member).	0.60
05/05/20	LJD	Review communication.	0.50
05/05/20	JD	Review of AlixPartners invoice with J. Lowne (Purdue).	0.30
05/05/20	JD	Review AlixPartners February invoice prior to review call with J. Lowne (Purdue).	0.40
05/06/20	JD	Call with J. DelConte and L. Donahue (both AlixPartners) re: case progress and go forward planning.	0.50
05/06/20	LJD	Call with J. DelConte and L. Donahue (both AlixPartners) re: case progress and go forward planning.	0.50
05/06/20	LJD	Review and comment on updated UCC deck.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/07/20	LJD	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT) and L. Donahue, J. DelConte (both AlixPartners).	0.90
05/07/20	LJD	Call with M. Huebner (Davis Polk) re: case update.	0.30
05/07/20	LJD	Review correspondence.	0.50
05/07/20	JD	Prepare for weekly update call with PJT, AlixPartners, DPW and management.	0.30
05/07/20	JD	Weekly update call with M. Kesselman, J. Lowne, R. Aleali (all Purdue), M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT) and L. Donahue, J. DelConte (both AlixPartners).	0.90
05/07/20	JD	Call with R. Aleali (Purdue) re: catch up post weekly call.	0.30
05/08/20	JD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	JD	Review status of open items in preparation for weekly update call.	0.30
05/08/20	JD	Call with R. Collura, J. DelConte (both AlixPartners) re: status of the intercompany and non-cash transfers report and special committee related work.	0.30
05/08/20	JD	Call with R. Aleali (Purdue) re: open items and go forward planning.	1.00
05/08/20	KM	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	RDS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/08/20	RC	McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	JDH	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	GJK	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	LJD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	LJD	Call with M. Huebner (Davis Polk) re: Purdue update.	0.30
05/08/20	MFR	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	FOS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	NAS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/08/20	IA	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	SJC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	SKL	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	ADD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/08/20	ADD	Prepare for Purdue AP Team update call.	0.40
05/08/20	ADD	Compile Rhodes' counterparties to use for search terms to redact for third-party information.	1.20
05/11/20	IA	Call with I. Arana and J. DelConte (both AlixPartners) re: current work plan.	0.30
05/11/20	JD	Call with I. Arana and J. DelConte (both AlixPartners) re: current work plan.	0.30
05/12/20	HK	Provide contract copies and supporting data per PrimeClerk request on behalf of contract counterparty.	0.20
05/13/20	JD	Review correspondence from C. Oluwole (Davis Polk) re: 2004 discovery requests.	0.30
05/13/20	JD	Prepare draft agenda for 5/14 call with Davis Polk, PJT, AlixPartners and Purdue.	0.70
05/15/20	JD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	
05/15/20	JD	Review family response to NY AG press release.	0.30
05/15/20	JD	Review and provide comments on the agenda for the weekly call.	0.20
05/15/20	KM	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	GJK	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	JDH	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	RC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	SJC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	IA	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/15/20	NAS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	FOS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	SKL	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	MFR	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	LJD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	ADD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/15/20	ADD	Prepare for AlixPartners Purdue engagement team updated call.	0.50
05/15/20	RDS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, A. DePalma, L. Donahue, J. Hecht, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.60
05/19/20	LJD	Call with PJT.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/19/20	JD	Call with E. Vonnegut (Davis Polk) re: confirmation process.	0.50
05/19/20	JD	Review and provide comments monthly Nalmefene spending report in order to get it posted for creditor advisors.	0.50
05/20/20	JD	Call with C. Oluwole (Davis Polk), R. Aleali (Purdue), T. Melvin (PJT), A. DePalma and J. DelConte (both AlixPartners) re: buyer log.	0.40
05/20/20	ADD	Call with C. Oluwole (Davis Polk), R. Aleali (Purdue), T. Melvin (PJT), A. DePalma and J. DelConte (both AlixPartners) re: buyer log.	0.40
05/21/20	JD	Participate in weekly update call with T. Coleman, J. Turner, J. O'Connell (all PJT), M. Huebner, T. Graulich, C. Robertson (all Davis Polk), M. Kesselman, J. Lowne, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: status update and go forward planning.	0.70
05/21/20	GJK	Participate in weekly update call with T. Coleman, J. Turner, J. O'Connell (all PJT), M. Huebner, T. Graulich, C. Robertson (all Davis Polk), M. Kesselman, J. Lowne, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: status update and go forward planning.	0.70
05/21/20	LJD	Participate in weekly update call with T. Coleman, J. Turner, J. O'Connell (all PJT), M. Huebner, T. Graulich, C. Robertson (all Davis Polk), M. Kesselman, J. Lowne, R. Aleali (all Purdue), L. Donahue, J. DelConte, G. Koch (all AlixPartners) re: status update and go forward planning.	0.70
05/22/20	LJD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	LJD	Update call with L. Donahue, J. DelConte (both	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/22/20	MFR	AlixPartners) re: staffing considerations. Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	SKL	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	FOS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	NAS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	IA	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	SJC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	GJK	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	RC	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	
05/22/20	JD	Review and provide comments on agenda for AlixPartners call.	0.30
05/22/20	JD	Update call with L. Donahue, J. DelConte (both AlixPartners) re: staffing considerations.	0.30
05/22/20	JD	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	KM	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/22/20	RDS	Call with I. Arana, S. Canniff, R. Collura, J. DelConte, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/23/20	JD	Review and provide comments on Prime Clerk invoice summary. Correspondence with Davis Polk re: same.	0.50
05/26/20	LJD	Review April financial results presentations and other pre-reads.	2.10
05/26/20	LJD	Review Rhodes organizational realignment deck and provide comments.	0.80
05/27/20	JD	Call with J. Doyle (Purdue), A. DePalma and J. DelConte (both AlixPartners) re: Rhodes Tech agreements.	0.30
05/27/20	ADD	Call with J. Doyle (Purdue), A. DePalma and J. DelConte (both AlixPartners) re: Rhodes Tech agreements.	0.30
05/29/20	RDS	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/29/20	ADD	McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	ADD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.40
05/29/20	ADD	Prepare for AlixPartners Purdue engagement team update meeting.	0.80
05/29/20	ADD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.40
05/29/20	JD	Review ongoing work streams and prepare agenda for weekly AlixPartners call.	0.80
05/29/20	JD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.50
05/29/20	RC	Call with J. DelConte and L. Donahue (both AlixPartners) re: case planning and staffing updates.	0.80
05/29/20	KM	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	LJD	Call with J. DelConte and L. Donahue (both AlixPartners) re: case planning and staffing updates.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
05/29/20	LJD	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	MFR	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	SKL	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	SJC	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	NAS	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
05/29/20	GJK	Call with S. Canniff, R. Collura, J. DelConte, A. DePalma, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, N. Simon, R. Sublett, (all AlixPartners) re: Weekly team update call.	0.80
		Total	<u>71.90</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	6.80	515.00	3,502.00
Sam K Lemack	3.60	515.00	1,854.00
Hart Ku	0.20	515.00	103.00
Nate A Simon	3.60	515.00	1,854.00
Fernando O Silva	2.00	645.00	1,290.00
Sam J Canniff	3.60	645.00	2,322.00
Isabel Arana de Uriarte	3.10	690.00	2,139.00
Jon D Hecht	2.00	690.00	1,380.00
Ryan D Sublett	2.80	735.00	2,058.00
Gabe J Koch	4.30	840.00	3,612.00
Mark F Rule	3.60	910.00	3,276.00
Jesse DelConte	16.50	950.00	15,675.00
Kevin M McCafferty	2.80	950.00	2,660.00
Richard Collura	3.60	1,090.00	3,924.00
Lisa Donahue	13.40	1,195.00	16,013.00
Total Hours & Fees	71.90		61,662.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/01/20	IA	Review weekly Paysource payments and latest fee applications filed to inform updated Purdue cash budget.	1.60
05/01/20	SKL	Created accounts payable release file.	0.90
05/01/20	SKL	Update the Rhodes forecast with the latest cash actuals and prepared the latest forecast-to-variance report.	1.60
05/01/20	SKL	Update the Purdue forecast with the latest cash actuals and prepared the latest forecast-to-variance report.	1.80
05/01/20	SKL	Finalize updates to the weekly cash report and circulated internally for final sign-off.	2.10
05/01/20	SKL	Finalize updates to the Rhodes Tech expense section of the latest Rhodes forecast.	1.60
05/03/20	IA	Review cash actuals report for week ended 04/24.	1.20
05/04/20	IA	Review short term collections report and forecast prepared by Purdue for week ended 05/08.	0.40
05/04/20	IA	Meeting with M. Hartley, I. Arana and S. Lemack (all AlixPartners) re: latest OCP updates and OCP tracking process.	0.50
05/04/20	IA	Meeting with I. Arana, S. Lemack (both AlixPartners) re: latest updates to the Purdue forecast.	0.40
05/04/20	IA	Review comments to Purdue cash actuals report and provided answers to rebates variance questions.	0.50
05/04/20	IA	Review May commercial rebates forecast prepared by client, to be incorporated into Purdue 13 week cash flow forecast.	1.70
05/04/20	SKL	Review the operating expenses from the 2020 Purdue budget and begin implementing in the Purdue forecast.	1.20
05/04/20	SKL	Finalize updates to the weekly cash report and circulated for final sign-off.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/04/20	SKL	Review the latest Purdue 2020 P&L provided by E. Nowakowski (Purdue) and continue to implement into the latest Purdue forecast.	2.60
05/04/20	SKL	Continue review of the latest Purdue 2020 P&L provided by E. Nowakowski (Purdue) and implementation into the Purdue forecast.	2.50
05/04/20	SKL	Meeting with I. Arana, S. Lemack (both AlixPartners) re: latest updates to the Purdue forecast.	0.40
05/04/20	SKL	Meeting with M. Hartley, I. Arana and S. Lemack (all AlixPartners) re: latest OCP updates and OCP tracking process.	0.50
05/04/20	SKL	Created accounts payable release file.	0.70
05/04/20	MH	Meeting with M. Hartley, I. Arana and S. Lemack (all AlixPartners) re: latest OCP updates and OCP tracking process.	0.50
05/04/20	JD	Review and provide comments on latest weekly cash forecast to actual report.	0.60
05/05/20	SKL	Created accounts payable release file.	0.90
05/05/20	SKL	Continue reviewing the operating expenses from the 2020 Purdue budget and implementation to the Purdue forecast.	2.40
05/05/20	SKL	Review the COGS section of the 2020 Purdue budget and begin implementing in the Purdue forecast.	2.40
05/05/20	SKL	Continue review of the COGS section of the 2020 Purdue budget and begin implementing in the Purdue forecast.	2.70
05/05/20	SKL	Meeting with I. Arana, S. Lemack (both AlixPartners) re: the Op. Ex. breakdown within the 2020 budget re: Purdue forecast.	0.80
05/05/20	IA	Meeting with I. Arana, S. Lemack (both AlixPartners) re:	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		the Op. Ex. breakdown within the 2020 budget re: Purdue forecast.	
05/05/20	IA	Review Purdue G&A by department budget breakdown to understand IAC charges, employee costs, and other credits to be adjusted in Purdue cash flow forecast.	2.40
05/05/20	IA	Summarize adjustments to Purdue G&A in cash flow forecast in schedule for discussion with cash team.	1.10
05/06/20	SKL	Review the docket for the latest fee applications filed by restructuring professionals and updated the restructuring professional tracker accordingly.	2.60
05/06/20	SKL	Review the docket for the latest fee applications filed by retained professionals and updated the retained professional tracker accordingly.	2.30
05/06/20	SKL	Created accounts payable release file.	0.90
05/06/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.30
05/06/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.00
05/06/20	IA	Review Purdue budget files and updated headcount plan to estimate benefits included in PL to be shown as payroll and benefits cash payments in 13 week forecast.	1.80
05/06/20	IA	Review filed fee applications against professional fees forecast to update estimates in latest version of Purdue cash flow forecast.	1.70
05/06/20	IA	Call with S. Lemack, I. Arana (both AlixPartners) re: Purdue cash flow forecast updates.	0.40
05/06/20	SKL	Call with S. Lemack, I. Arana (both AlixPartners) re: Purdue cash flow forecast updates.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/07/20	IA	Update Avrio dashboard to show April consumption and market share data by brand and product.	2.30
05/07/20	SKL	Finalize review and reconciliation of the latest Paysource transaction report and updated the cash report accordingly.	1.00
05/07/20	SKL	Prepare the updated IAC transaction summaries and prepared list of open-items for J. Liceaga (TXP) and E. Nowakowski (Purdue).	1.40
05/07/20	SKL	Continue to finalize updates to the Purdue forecast and begin reviewing the forecast-to-actual variances.	2.70
05/07/20	SKL	Update the weekly cash report with the latest feedback provided by J. Liceaga (TXP).	1.10
05/07/20	SKL	Consolidated Monthly Operating Reports filed to date and circulated to R. Aleali (Purdue).	0.40
05/07/20	SKL	Prepare updated critical vendor analysis and breakdown per J. Lowne (Purdue) request.	0.50
05/07/20	SKL	Prepare the weekly cash reporting deck.	1.80
05/07/20	SKL	Created accounts payable release file.	0.80
05/07/20	IA	Update Purdue cash forecast for Rhodes budgeted sales, API purchases, North Carolina charges, and other shared services payments.	1.80
05/07/20	IA	Perform analysis of quarterly sales, collections, and rebate payments to adjust Purdue budget amounts in cash flow forecast.	2.40
05/07/20	IA	Update G&A expenses in Purdue cash flow forecast to exclude credits for amounts charged or paid to IACs .	1.70
05/07/20	IA	Update payroll and benefit estimates in Purdue forecast, pulling out salaries and benefit charges from PL expense categories and reconciling to latest employee roster and	2.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		headcount plan.	
05/07/20	JD	Correspondence with J. Lowne, H. Benson (both Purdue), J. DelConte, S. Lemack (both AlixPartners) re: critical vendor payments.	0.30
05/08/20	SKL	Finalize updates to the Rhodes forecast and put together the Rhodes forecast-to-actuals variance report.	2.10
05/08/20	SKL	Finalized updates to the weekly cash report and finished preparing the deck.	1.80
05/08/20	SKL	Prepare and update the latest cash forecast deck.	2.30
05/08/20	SKL	Created accounts payable release file.	0.90
05/08/20	IA	Review Q1 rebate payments and update rebates forecast in updated Purdue 13 week cash flow model.	1.90
05/08/20	IA	Update bankruptcy professional fees forecast in Purdue 13 week cash flow model.	0.60
05/08/20	IA	Update OCP legal fees and retained firms forecast in Purdue 13 week cash flow model.	1.70
05/08/20	IA	Update IAC transactions forecast in Purdue 13 week cash flow model.	1.80
05/08/20	IA	Update summary schedules (IAC, rebates, professional fees) in Purdue 13 week cash flow model, to be included in updated forecast overview presentation.	2.20
05/08/20	SKL	Finalize updates to the Purdue and Rhodes forecast and begin implementing relevant information into the forecast deck.	2.20
05/09/20	SKL	Finalize updates to the latest cash forecast and circulated internally for final review.	1.40
05/09/20	IA	Review updated cash forecast overview presentation and provided comments.	1.30
05/11/20	IA	Follow up on payments of professional fees for filed fee	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		applications.	
05/11/20	SKL	Created accounts payable release file.	0.70
05/11/20	SKL	Update the Rhodes cash forecast based on the latest feedback provided.	2.20
05/11/20	SKL	Finalize updates to the latest Rhodes and Purdue forecast and circulated internally for sign-off.	2.50
05/11/20	SKL	Consolidated monthly flash reports and distributed to R. Aleali (Purdue) per her request.	0.40
05/11/20	SKL	Finalize updates to the 05/01 cash report and circulated internally for sign-off.	1.10
05/11/20	SKL	Prepare 13-week comparison of cash actuals and the latest cash forecast and circulated internally for review and sign-off.	1.40
05/11/20	JD	Review and provide comments on latest updated cash flow forecast and last week's forecast to actual report.	1.80
05/12/20	JD	Review and comment on final draft of the cash forecast and cash forecast to actual report.	0.60
05/12/20	SKL	Prepare additional updates to the rebates section of the Rhodes forecast and re-circulated for final sign-off.	1.20
05/12/20	SKL	Prepare breakdown of outstanding prepetition invoices and ensured an invoice related to a particular contract assumption was included in the daily invoice release file.	0.60
05/12/20	SKL	Review and reconcile the March Board deck and begin preparing the March Flash Report accordingly.	2.60
05/12/20	SKL	Created accounts payable release file.	0.90
05/12/20	SKL	Finalize updates to the March Flash report, put together a breakdown of slides included/excluded from the March Board deck, and circulated internally for sign-off.	2.80
05/12/20	MH	Discussion with C. MacDonald (Purdue), and M. Hartley,	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		S. Lemack (both AlixPartners) re: OCP tracking and invoices submitted to docket.	
05/12/20	IA	Review comments to cash report, update forecast model and provide answers before resubmitting for internal approvals.	1.90
05/12/20	IA	Update Rhodes intercompany transactions in Purdue cash forecast model.	1.70
05/12/20	SKL	Discussion with C. MacDonald (Purdue), and M. Hartley, S. Lemack (both AlixPartners) re: OCP tracking and invoices submitted to docket.	0.70
05/13/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.10
05/13/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.80
05/13/20	SKL	Review and reconcile the latest investment activity and circulated list of open items to J. Liceaga (TXP) to provide additional insight/detail.	1.20
05/13/20	SKL	Process final updates to the other receipts section of the Purdue forecast per J. Lowne (Purdue) feedback and re-circulated for final sign-off.	1.30
05/13/20	SKL	Review and reconcile the latest Purdue and Rhodes weekly sales reports and circulated to the company for final sign-off.	1.20
05/13/20	SKL	Created accounts payable release file.	0.90
05/13/20	JD	Review comments from J. Lowne (Purdue) re: latest cash flow forecast.	0.30
05/14/20	JD	Review current cash balances and cash balances listed in the latest MOR.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/14/20	SKL	Created accounts payable release file.	0.80
05/14/20	SKL	Review and reconcile the latest feedback provided by J. Liceaga (TXP) re: Investment activity and updated the weekly cash report accordingly.	1.30
05/14/20	SKL	Finalize updates to the Rhodes summary re: weekly cash report.	1.20
05/14/20	SKL	Finalize updates to the Purdue summary re: weekly cash report.	1.30
05/14/20	SKL	Discussion with M. Hartley, S. Lemack (both AlixPartners) re: indemnification cost approval process.	0.60
05/14/20	SKL	Review and reconcile the April OCP payment activity and begin preparing the April Monthly Operating Report accordingly.	1.80
05/14/20	SKL	Finalize review of IAC cash activity from week ended 05/08 and prepared list of open items for E. Nowakowski (Purdue) and J. Liceaga (TXP).	1.30
05/14/20	IA	Review docket for latest fee applications filed.	0.80
05/15/20	SKL	Review and reconcile the April cash activity and prepared the updated cash activity slides for the April Monthly Operating Report.	2.40
05/15/20	SKL	Review and reconcile the April investment activity and prepared the updated investment activity slide for the April Monthly Operating Report.	2.20
05/15/20	SKL	Updated the Purdue forecast with the latest cash activity and prepared the Purdue forecast-to-actuals slides accordingly re: weekly cash report.	1.30
05/15/20	SKL	Created accounts payable release file.	0.80
05/18/20	SKL	Created accounts payable release file.	0.80
05/18/20	SKL	Review and reconcile the latest rebate information	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		provided by J. Liceaga (TXP) and updated the cash report deck accordingly.	
05/18/20	SKL	Prepare the latest professional payment piece of the April Monthly Operating Report and circulated to the Purdue team for final sign-off.	2.70
05/18/20	SKL	Refreshed the professional payment piece of the April Monthly Operating Report based on the feedback provided internally and circulated for final sign-off.	1.80
05/18/20	SKL	Finalize updates to the March flash report and circulated to J. Lowne, R. Aleali (both Purdue) for final sign-off.	2.10
05/18/20	IA	Review professional fee payment timing based on recently filed fee applications.	1.10
05/18/20	JD	Review professional fee payment status.	0.40
05/19/20	IA	Review and provide comments to cash report for week ended 05/08/2020.	1.30
05/19/20	SKL	Prepare updated reconciliation of the latest critical vendor inquiries and prepared analysis on the latest executed critical vendor agreement.	2.30
05/19/20	SKL	Finalize updates to the latest cash report and circulated to J. Lowne, R. Aleali (both Purdue) for final sign-off.	2.50
05/19/20	SKL	Created accounts payable release file.	0.80
05/19/20	SKL	Refreshed the March flash report with the latest feedback provided and distributed to the Davis Polk team to begin the production process.	0.70
05/19/20	SKL	Review latest OCP vendor ID inquiry and updated the retained professional tracker accordingly.	1.10
05/20/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/20/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.70
05/20/20	SKL	Review and reconcile the latest investment and IAC activity and circulated list of open items to J. Liceaga (TXP) to provide additional insight and detail.	2.60
05/20/20	SKL	Created accounts payable release file.	1.70
05/21/20	SKL	Update the Purdue forecast with the latest cash actuals and prepared the latest forecast-to-actuals.	2.10
05/21/20	SKL	Update the Rhodes forecast with the latest cash actuals and prepared the latest forecast-to-actuals.	1.30
05/21/20	SKL	Created accounts payable release file.	1.80
05/21/20	SKL	Prepare the 05.08 weekly cash report and circulated internally for final sign-off.	2.40
05/21/20	MH	Meeting with D. Sanil (Purdue), F. Bell (LPW), M. Hartley, S. Lemack (both AlixPartners) re: open LPW Training Partner payment inquiries.	0.40
05/21/20	SKL	Meeting with D. Sanil (Purdue), F. Bell (LPW), M. Hartley, S. Lemack (both AlixPartners) re: open LPW Training Partner payment inquiries.	0.40
05/21/20	JD	Review and provide comments on cash report for week ended 5/8.	0.60
05/22/20	SKL	Review and reconcile the latest Prime Clerk invoices and updated the restructuring professionals tracker accordingly.	1.80
05/22/20	SKL	Prepare updated Prime Clerk invoice/payment breakdown and rollforward and circulated internally for final sign-off.	2.70
05/22/20	SKL	Update the Rhodes fee for service and private insurance section of the March Customer Programs report.	2.50
05/22/20	SKL	Created accounts payable release file.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
05/26/20	SKL	Review and reconcile latest critical vendor breakdown and provided vendor update.	1.30
05/26/20	SKL	Created accounts payable release file.	0.80
05/26/20	SKL	Continue to update the 05/15 weekly cash report and provided updated list of outstanding inquiries to E. Nowakowski (Purdue).	2.40
05/26/20	SKL	Review the docket for the latest restructuring fee applications and updated the restructuring tracker accordingly.	1.40
05/26/20	SKL	Review the docket for the latest retained professional fee applications and updated the retained professional tracker accordingly.	1.20
05/26/20	SKL	Update the Rhodes summary of the March Customer Programs report.	1.00
05/27/20	SKL	Review and reconcile the latest Paysource transaction report and updated the cash report accordingly.	1.90
05/27/20	SKL	Review and reconcile the latest investment and IAC activity and circulated list of open items to J. Liceaga (TXP) to provide additional background and support.	1.60
05/27/20	SKL	Review and reconcile the latest EastWest transaction report provided by J. Liceaga (TXP) and updated the cash report accordingly.	2.50
05/27/20	SKL	Created accounts payable release file.	1.20
05/28/20	SKL	Created accounts payable release file.	1.50
05/28/20	SKL	Update the Rhodes forecast with the latest cash actuals and prepared the latest forecast-to-actuals.	1.50
05/28/20	SKL	Update the Purdue forecast with the latest cash actuals and prepared the latest forecast-to-actuals.	2.20
05/28/20	SKL	Prepare the updated 5/22 weekly cash report and	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		prepared list of open items for E. Nowakowski (Purdue) to provide additional detail on.	
05/29/20	SKL	Prepare the monthly OCP report with April activity.	1.30
05/29/20	SKL	Continue to updated the latest weekly cash report with the latest feedback provided by E. Nowakowski (Purdue).	2.30
05/29/20	SKL	Review and reconcile the latest Purdue weekly sales report and circulated for final sign-off.	1.10
05/29/20	SKL	Review and reconcile the latest Rhodes weekly sales report and circulated for final sign-off (cont.).	1.00
05/29/20	SKL	Created accounts payable release file.	0.70
Total			<u>215.00</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	166.30	515.00	85,644.50
Isabel Arana de Uriarte	42.20	690.00	29,118.00
Michael Hartley	1.60	840.00	1,344.00
Jesse DelConte	4.90	950.00	4,655.00
Total Hours & Fees	215.00		120,761.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/01/20	ADD	Draft correspondence to request approval to upload files requested by the UCC to the data room.	0.50
05/01/20	ADD	Update categories of files produced in response to diligence requests at request of Davis Polk.	0.50
05/01/20	ADD	Update family job title history chart using feedback received from Purdue Client contact, prepared in response to diligence request.	2.10
05/01/20	ADD	Update diligence request tracker in preparation for update call.	0.90
05/01/20	ADD	Upload files provided in response to diligence requests and processed by Davis Polk to the Intralinks virtual dataroom.	1.70
05/01/20	ADD	Review and follow up with outstanding UCC and ad-hoc committee diligence requests.	1.70
05/01/20	ADD	Call with Davis Polk diligence team re: production for upload to data room.	0.60
05/02/20	ADD	Upload files processed and designated by Davis Polk to the data room.	3.20
05/04/20	ADD	Upload documentation provided by Davis Polk eDiscovery team to the dataroom.	0.80
05/04/20	ADD	Review Intralinks to confirm all files from previous week's production were upload.	2.10
05/04/20	ADD	Compile and format documentation submitted in response to diligence requests for processing.	1.70
05/04/20	ADD	Update data room folder naming convention at request of Davis Polk and move files to appropriate location.	1.40
05/04/20	ADD	Review Rhodes board presentation and identify third-party information for redactions.	1.30
05/04/20	ADD	Discussion with Intralinks support for a view only platform	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		options for data room to accommodate committee diligence requests.	
05/04/20	ADD	Draft correspondence to request approval to upload documentation to the data room.	0.60
05/04/20	IA	Meeting with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Fogel, M. Ronning (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) and J. DelConte, I. Arana, R. Sublett, K. McCafferty (all AlixPartners) re: updated business plan.	1.60
05/04/20	JD	Meeting with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Fogel, M. Ronning (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) and J. DelConte, I. Arana, R. Sublett, K. McCafferty (all AlixPartners) re: updated business plan.	1.60
05/04/20	KM	Meeting with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Fogel, M. Ronning (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) and J. DelConte, I. Arana, R. Sublett, K. McCafferty (all AlixPartners) re: updated business plan.	1.60
05/05/20	JD	Review and revise proposed responses to UCC diligence questions.	0.50
05/05/20	JD	Review and draft responses to updated diligence questions from M. Atkinson (Province).	0.70
05/05/20	JD	Review and provide comments on proposed responses from the Company to Ad Hoc Committee business plan diligence questions.	0.90
05/05/20	JD	Review summary of Sackler family company position titles.	0.30
05/05/20	JD	Review diligence files prior to them being finalized and posted.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/05/20	ADD	Review and redaction of Purdue Pharma Inc board minutes from 2007 - 2008.	2.60
05/05/20	ADD	Review outstanding diligence requests and develop strategy for obtaining responsive materials.	2.30
05/05/20	ADD	Call with Davis Polk diligence team re: outstanding diligence requests.	0.50
05/05/20	ADD	Incorporate feedback and update Sackler family positions chart.	1.50
05/06/20	ADD	Compile and incorporate responses to UCC diligence questions.	1.90
05/06/20	ADD	Compile diligence responses and draft correspondence seeking approval to upload document to the data room.	2.50
05/06/20	ADD	Review and redaction of Purdue Pharma Inc board minutes from 2009 - 2011.	2.80
05/06/20	ADD	Review Rhodes board materials for third-party confidential information and provide redaction to Davis Polk.	2.70
05/06/20	ADD	Call with C. Oluwole, E. Diggs (both Davis Polk), R. Aleali (Purdue) and J. DelConte and A. DePalma (both AlixPartners) re: Sackler family designations.	0.40
05/06/20	JD	Call with C. Oluwole, E. Diggs (both Davis Polk), R. Aleali (Purdue) and J. DelConte and A. DePalma (both AlixPartners) re: Sackler family designations.	0.40
05/06/20	JD	Correspondence with J. Lowne (Purdue) and J. DelConte, A. DePalma (both AlixPartners) re: open UCC diligence responses.	0.80
05/06/20	JD	Review quarterly financial information provided to date and monthly flash reports posted to date in order to draft a response to outstanding UCC diligence requests.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/06/20	JD	Review draft responses from T. Au and D. Rosen (both Purdue) re: AHC diligence requests.	0.50
05/06/20	JD	Review and provide comments on latest UCC diligence tracker from PJT.	0.80
05/07/20	JD	Review various diligence items posted to date per AHC request to disclose certain information on a non-PEO basis to their committee members.	1.60
05/07/20	ADD	Review board materials to verify job titles for insiders and verify start/end dates.	3.10
05/07/20	ADD	Review and redaction of Purdue Pharma Inc board minutes from 2012 - 2013.	2.70
05/07/20	ADD	Research request for contract using Purdue's contract management system and other contract repositories.	1.40
05/07/20	ADD	Research and identify prior production of legal fee detail.	0.60
05/07/20	ADD	Compile business development agreements for processing and upload to the data room.	0.30
05/08/20	ADD	Compile and incorporate responses to UCC diligence questions.	1.80
05/08/20	ADD	Research and test view only access feature to grant access to various parties.	0.80
05/08/20	ADD	Draft correspondence to request approval and feedback for documents submitted in response to diligence requests.	0.40
05/08/20	ADD	Call with PJT re: outstanding diligence request.	0.20
05/08/20	ADD	Upload files provided by Davis Polk eDiscovery team to the dataroom for the UCC.	2.80
05/11/20	ADD	Compile April liabilities subject to compromise analysis for Purdue Finance team.	2.80
05/11/20	ADD	Upload files to the data room for the committee to access.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/11/20	ADD	Compile and format material submitted in response to diligence request in preparation for upload to the data room	2.70
05/11/20	JD	Review current IP complaints with Intellipharmaceutics prior to providing to the UCC.	0.80
05/11/20	JD	Initial review of existing creditor presentation for potential redaction.	0.70
05/11/20	JD	Review final version of UCC diligence question responses.	0.30
05/11/20	JD	Call with J. Kochian, D. Vondle (both Akin), M. Atkinson, S. Morrison (both Province), K. Sheridan (Jefferies), J. Normile (Jones Day), J. Lowne, P. Strassburger (both Purdue), T. Melvin, J. Turner (both PJT) re: OxyContin LOE.	0.70
05/11/20	JD	Correspondence with C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: board materials diligence requests.	0.30
05/12/20	ADD	Compile responses to diligence request in preparation for upload to the data room.	2.90
05/12/20	ADD	Request approval to upload materials submitted in response to diligence requests to the data room.	0.40
05/12/20	ADD	Upload files submitted in response to diligence request to the data and permission stakeholders.	1.40
05/12/20	ADD	Identify and review material contracts in response to diligence requests.	2.80
05/12/20	ADD	Draft correspondence to identify potential avenues to acquire materials in response to diligence requests.	0.60
05/13/20	ADD	Research and document D&O title history in response to diligence request.	2.10
05/13/20	ADD	Review and compile responses to diligence requests from the ad-hoc committee.	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/13/20	ADD	Compile responses for diligence requests reviewing for consistency and formatting.	2.40
05/13/20	JD	Review latest draft Sackler title history draft.	0.20
05/13/20	JD	Review and provide comments on the latest non-PEO creditor business plan presentation.	0.80
05/14/20	JD	Call with J. DelConte, A. DePalma (both AlixPartners) re: diligence process.	0.40
05/14/20	ADD	Call with J. DelConte, A. DePalma (both AlixPartners) re: diligence process.	0.40
05/14/20	ADD	Compile responses to AHC diligence tracker and circulate updated document for review.	1.70
05/14/20	ADD	Review and redact materials submitted in response to diligence request for third-party confidential information.	1.20
05/14/20	ADD	Update job title history compiled in response to committee diligence request.	0.70
05/14/20	ADD	Review outstanding diligence requests, responses received and update request tracker.	1.20
05/14/20	ADD	Compile and format materials submitted in response to diligence requests for processing for upload to data room.	1.90
05/15/20	ADD	Upload files from weekly production to data room for the Committees to access.	1.20
05/15/20	ADD	Locate and review contracts database to identify material contracts.	1.40
05/15/20	JD	Review final diligence materials to be posted in response to UCC diligence questions.	0.50
05/17/20	JD	Review follow up questions from AHC re: non-PEO presentation information.	0.60
05/18/20	JD	Review latest diligence list from FTI and look into open tax questions.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/18/20	JD	Review comments from management on the latest AHC/FTI diligence request responses.	0.50
05/18/20	IA	Review and redact 2019 cash reports to be shared under protective order process.	2.60
05/19/20	ADD	Compile and format responses to diligence request list in preparation for upload to the data room.	2.40
05/19/20	ADD	Review materials submitted in response to diligence requests for potential third-party confidentiality issues.	2.80
05/21/20	JD	Review draft responses from management re: Duff & Phelps questions.	0.70
05/22/20	ADD	Compile and format files provided in response to diligence requests for upload to data room.	2.50
05/22/20	ADD	Review contracts matrix in response to request for information on active Rhodes Tech contracts.	0.80
05/22/20	ADD	Review outstanding diligence requests and update diligence tracker.	0.90
05/26/20	ADD	Meeting with Davis Polk diligence team and Purdue Associate General Counsel re: third party confidentiality issues.	0.40
05/26/20	ADD	Compile documentation and written responses submitted in response to diligence requests in preparation for upload to the data room.	2.70
05/26/20	ADD	Research entities submitted by Davis Polk for business relationships to identify third party confidentiality issues.	2.30
05/26/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: discuss updates to the UCC's tax request tracker.	0.30
05/26/20	ADD	Review responses to outstanding diligence requests and update diligence tracker.	1.30
05/26/20	JD	Review side by side analysis and retention and severance	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/26/20	JD	assumptions to respond to UCC diligence questions. Correspondence with B. Schrag (Prime Clerk) re: Prime Clerk invoice analysis. Update analysis per comments.	0.50
05/27/20	JD	Call with J. Turner, T. Melvin (both PJT), J. Lowne, M. Kesselman, R. Aleali, D. Rosen (all Purdue), M. Florence (Skadden), J. Buchu (King & Spalding) re: upcoming Duff & Phelps prep call.	1.20
05/27/20	SJC	Review and redact 2008 board meeting minutes in preparation for processing an upload to data room (Continue).	2.00
05/27/20	SJC	Review and redact 2008 board meeting minutes in preparation for processing an upload to data room.	3.00
05/27/20	SJC	Review and redact 2009 board meeting minutes in preparation for processing an upload to data room.	3.00
05/27/20	ADD	Review options to set up data room to provide access to different parties.	0.50
05/28/20	ADD	Review diligence questions and compare to previous request to leverage other previously submitted responses.	1.80
05/28/20	ADD	Compile and format materials submitted in response to diligence request in preparation for upload to the data room.	2.10
05/28/20	ADD	Call with Davis Polk re: response to tax requests and outstanding tax request.	0.50
05/28/20	ADD	Call with Davis Polk re: UCC tax request meeting.	0.60
05/28/20	SJC	Review and redact 2010 board meeting minutes in preparation for processing an upload to data room.	3.00
05/28/20	SJC	Review and redact 2010 board meeting minutes in preparation for processing an upload to data room (Continue).	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
05/28/20	SJC	Review and redact 2011 board meeting minutes in preparation for processing an upload to data room.	2.00
05/28/20	JD	Meeting with J. Turner, T. Melvin (both PJT), J. Lowne, E. Ruiz, D. Rosen, R. Fanelli (all Purdue), R. Levy, J. Feltman, R. Schwartz, A. Chrysostomou (all Duff & Phelps) re: PHI forecasts.	1.00
05/29/20	JD	Review updated business plan diligence questions from FTI.	0.30
05/29/20	JD	Review final Duff & Phelps diligence question responses in advance of the call next Tuesday.	0.80
05/29/20	SJC	Review and redact 2011 board meeting minutes in preparation for processing an upload to data room (Continue).	3.00
05/29/20	SJC	Review and redact 2011 board meeting minutes in preparation for processing an upload to data room.	2.00
05/29/20	SJC	Review and redact 2012 board meeting minutes in preparation for processing an upload to data room.	2.50
05/29/20	ADD	Update diligence tracker in preparation for AG Core team meeting.	0.40
05/29/20	ADD	Review debtor tax returns to confirm that tax returns received were uploaded.	1.40
05/29/20	ADD	Set up share folder for client to upload documents and other diligence materials.	0.40
05/29/20	ADD	Set up Intralinks dataroom for Project Catalyst.	1.20
05/29/20	ADD	Upload to the data room production provided by DPW eDiscovery team and provide access to designated parties.	2.10
05/29/20	ADD	Review and analyze Rhodes invoices to identify material contracts.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
			Total
			<u>160.60</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	110.20	515.00	56,753.00
Sam J Canniff	23.50	645.00	15,157.50
Isabel Arana de Uriarte	4.20	690.00	2,898.00
Kevin M McCafferty	1.60	950.00	1,520.00
Jesse DelConte	21.10	950.00	20,045.00
Total Hours & Fees	160.60		96,373.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
05/11/20	ADD	Call with A. DePalma, M. Hartley (both AlixPartners) re: transition of Monthly Operating Report.	0.50
05/11/20	NAS	Request information from Purdue/TXP related to insider payments section of Monthly Operating Report.	0.80
05/11/20	MH	Call with A. DePalma, M. Hartley (both AlixPartners) re: transition of Monthly Operating Report.	0.50
05/12/20	NAS	Correspondence with Purdue/TXP re: insider payments section of April 2020 MOR.	0.50
05/15/20	NAS	Analyze data for insider payments section of April 2020 MOR.	0.70
05/15/20	MH	Participate in OCP/Retained Professional catch-up call re: April Monthly Operating Report with M. Hartley, S. Lemack (both AlixPartners).	0.90
05/15/20	SKL	Participate in OCP/Retained Professional catch-up call re: April Monthly Operating Report with M. Hartley, S. Lemack (both AlixPartners).	0.90
05/18/20	NAS	Prepare insider payments section of April 2020 MOR.	0.80
05/18/20	JD	Review information to be provided to the UST prior to asking for an extension on MOR filing.	0.70
05/19/20	JD	Correspondence with Davis Polk and the US Trustee's office re: MOR timing.	0.60
05/20/20	NAS	Review Insider Payments section of Monthly Operating Report for accuracy.	0.50
05/21/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: open prepetition vendor payment inquiries and prepared for upcoming meeting with LPW Training Partners.	0.70
05/21/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: open prepetition vendor payment inquiries and	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
		prepared for upcoming meeting with LPW Training Partners.	
05/26/20	KAS	Email B. Filler and L. Verry (both AlixPartners) request to update retention pleadings.	0.20
05/26/20	KAS	Review and edit draft retention pleadings.	0.70
05/26/20	LCV	Assist with revisions to draft retention documents.	0.30
05/27/20	KAS	Review updated draft retention pleadings from B. Filler (AlixPartners).	0.70
05/27/20	ADD	Review outstanding diligence request and update diligence request tracker to document outstanding requests.	2.70
05/27/20	ADD	Review and research requests for additional information re: interested party list entity clarifications.	2.20
05/28/20	ADD	Compile and prepare April MOR for signature from Purdue.	1.30
05/28/20	ADD	Research options for new Intralinks data room.	0.90
05/28/20	JD	Review draft monthly operating report prior to filing it on the docket.	0.70
05/29/20	MH	Review MOR.	0.40
		Total	18.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Laurie C Verry	0.30	510.00	153.00
Kaitlyn A Sundt	1.60	510.00	816.00
Andrew D DePalma	7.60	515.00	3,914.00
Sam K Lemack	1.60	515.00	824.00
Nate A Simon	3.30	515.00	1,699.50
Michael Hartley	2.50	840.00	2,100.00
Jesse DelConte	2.00	950.00	1,900.00
Total Hours & Fees	18.90		11,406.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/01/20	NAS	Call with N. Simon, G. Koch (both AlixPartners) to compare latest Mundipharma business plan model output with management's revised forecast.	0.70
05/01/20	NAS	Analyze Mundipharma net working capital by region as shown in most recent balance sheet and income statement.	2.40
05/01/20	GJK	Call with J. Arsic (PJT), N. Simon, G. Koch (both AlixPartners) re: latest draft of Mundipharma business plan model; follow-up discussion with N. Simon (AlixPartners) afterwards.	0.80
05/01/20	GJK	Call with N. Simon, G. Koch (both AlixPartners) to compare latest Mundipharma business plan model output with management's revised forecast.	0.70
05/01/20	GJK	Mundipharma NWC review and follow up.	0.50
05/01/20	GJK	Draft background slides for Mundipharma interim report.	3.00
05/01/20	GJK	Analysis of Mundipharma revised business plan.	2.00
05/01/20	NAS	Update Mundipharma individual country/product P&Ls to incorporate revisions to management's forecast.	1.40
05/01/20	NAS	Consolidate and prioritize remaining open items for Mundipharma business plan model.	0.40
05/01/20	NAS	Separate Israel joint venture and allocate other line items in Mundipharma business plan model.	2.00
05/01/20	NAS	Call with J. Arsic (PJT), N. Simon, G. Koch (both AlixPartners) re: latest draft of Mundipharma business plan model; follow-up discussion with G. Koch (AlixPartners) afterwards.	0.80
05/01/20	IA	Call with I. Arana, J. DelConte (both AlixPartners), K. Laurel, J. Lowne (both Purdue) re: PHI scenarios requested by the committees.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/01/20	IA	Review G&A detail file for Purdue 2020 budget to be incorporated into cash flow model.	1.20
05/01/20	JD	Call with I. Arana, J. DelConte (both AlixPartners), K. Laurel, J. Lowne (both Purdue) re: PHI scenarios requested by the committees.	0.60
05/01/20	JD	Review summary materials re: COVID donation recipients.	0.40
05/01/20	GJK	Analysis of analgesics product category for draft Mundipharma diligence interim report slides.	3.50
05/01/20	RDS	Call with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: financial benefits of potential partnership.	1.00
05/01/20	RDS	Call with R. Shamblan, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst insourcing savings analysis.	0.90
05/01/20	RDS	Review case progress and follow up on CPP and Project Catalyst.	0.40
05/01/20	KM	Analysis re: Project Catalyst insourcing savings.	1.00
05/01/20	KM	Call with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: financial benefits of potential partnership.	1.00
05/01/20	KM	Prepare Rhodes finance re-engineering stages of excellence.	0.90
05/01/20	KM	Analysis re: Rhodes finance stages of excellence.	0.60
05/01/20	KM	Call with R. Shamblan, D. Fogel (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst insourcing savings analysis.	0.90
05/01/20	KM	Analysis and slide creation re: Project Catalyst insourcing savings analysis.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/02/20	GJK	Analysis of Canada region for draft Mundipharma diligence interim report slides.	3.00
05/02/20	GJK	Create comparative geographic regions slides for draft Mundipharma diligence interim report slides.	3.00
05/02/20	GJK	Analyze variance between OB 2020 and April Revised Mundipharma business plans.	2.00
05/02/20	GJK	Call with J. Turner (PJT) re: potential Mundipharma transaction structure.	0.30
05/03/20	GJK	Create slides on key products by geographic region for Mundipharma interim diligence report.	4.00
05/03/20	GJK	Assess S&P and MA spend for certain products for Mundipharma interim diligence report.	1.00
05/03/20	GJK	Update base case deck for Mundipharma interim diligence report.	3.00
05/03/20	JD	Review potential segment financial materials for 5/4 call with creditors.	0.70
05/03/20	JD	Review diligence questions from M. Atkinson (Province) and proposed responses from management re: business plan presentation.	0.80
05/03/20	NAS	Revise individual country P&L in Mundipharma business plan model.	2.30
05/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to plan Mundipharma diligence priorities for week.	0.50
05/04/20	NAS	Review latest version of Mundipharma business plan model for completeness.	1.60
05/04/20	NAS	Revise P&L format in Mundipharma business plan model to match new format used in management forecast.	0.40
05/04/20	NAS	Translate country adjustments in Mundipharma business plan model to consolidated P&L.	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/04/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma business plan model.	1.20
05/04/20	NAS	Revise Mundipharma China/LAM section of diligence report.	2.00
05/04/20	NAS	Review draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	0.60
05/04/20	NAS	Compare Mundipharma China EBIT in model relative to management forecast.	1.40
05/04/20	NAS	Revise process overview and Mundipharma Europe section of diligence report.	2.90
05/04/20	NAS	Edit and update to Mundipharma diligence report draft.	1.00
05/04/20	IA	Review March results board update presentation, to be used for March monthly flash report.	1.40
05/04/20	JD	Review updated Rhodes and Purdue NSP and NPA data to be uploaded for creditor advisors.	0.40
05/04/20	JD	Review March financial overview presentation in advance of creating the monthly flash report for creditors.	1.00
05/04/20	KM	Edit deck re: finance re-engineering kickoff presentation.	0.80
05/04/20	KM	Analysis and report creation re. Finance Stages of Excellence survey.	1.90
05/04/20	KM	Prepare deck re: finance re-engineering kickoff presentation.	2.30
05/04/20	JD	Correspondence with R. Aleali (Purdue) and J. Turner (PJT) re: Project Catalyst.	0.30
05/04/20	JD	Review follow up questions from Province re: business plan overview conversation.	0.40
05/04/20	JD	Review RALP segment financials in order to be uploaded to the data room.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/04/20	GJK	Call with G. Koch, N. Simon, (both AlixPartners) to plan Mundipharma diligence priorities for week.	0.50
05/04/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma business plan model.	1.20
05/04/20	GJK	Review draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	0.60
05/04/20	GJK	Draft updates to general overview and diligence process slides for Mundipharma interim diligence report.	3.00
05/04/20	GJK	Draft key findings overview for analgesic category for Mundipharma interim diligence report.	3.50
05/04/20	GJK	Update analysis around analgesics based on revised model (Matla format).	3.00
05/04/20	GJK	Finalize draft section for analgesics for Mundipharma interim diligence report.	2.40
05/04/20	JD	Correspondence with J. Turner (PJT) and J. Lowne (Purdue) re: follow up questions from Jefferies after the business plan call.	0.70
05/04/20	RDS	Meeting with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Fogel, M. Ronning (all Purdue), J. Turner, R. Schnitzler, T. Melvin (all PJT) and J. DelConte, I. Arana, R. Sublett, K. McCafferty (all AlixPartners) re: updated business plan.	1.60
05/04/20	RDS	Prepare finance transformation interview / survey data.	0.30
05/05/20	RDS	Review finance transformation meeting presentation and agenda in preparation of RALP meeting.	0.80
05/05/20	RDS	Build spider charts for finance organization assessment data.	1.40
05/05/20	RDS	Call with D. Lundi, D. Fogel, R. Shamblen, V. Mancinelli and others (all Purdue) and J. DelConte, K. McCafferty	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		and R. Sublett (all AlixPartners) re: finance transformation.	
05/05/20	RDS	Assemble materials and setup meetings for finance transformation next steps.	0.90
05/05/20	GJK	Update China analysis based on revised Malta model for Mundipharma interim diligence report.	3.50
05/05/20	GJK	Drafting Mundipharma diligence report - China product sales pages.	3.50
05/05/20	GJK	Update analysis of Europe and Canada analgesic products for Mundipharma interim diligence report.	3.00
05/05/20	GJK	Update analysis of Europe and Canada analgesic products for Mundipharma interim diligence report (cont).	2.00
05/05/20	GJK	Partial participation in call with G. Koch, N. Simon (both AlixPartners), J. Arsic, I. Mian (both PJT) re: latest drafts of Mundipharma model and report.	0.50
05/05/20	GJK	Review latest draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	1.00
05/05/20	JD	Call with D. Lundi, D. Fogel, R. Shamblen, V. Mancinelli and others (all Purdue) and J. DelConte, K. McCafferty and R. Sublett (all AlixPartners) re: finance transformation.	1.50
05/05/20	JD	Correspondence with K. Laurel and J. Lowne (both Purdue) re: contract sales force.	0.30
05/05/20	JD	Review materials re: proposed licensing transaction.	0.70
05/05/20	KM	Prepare for finance re-engineering workshop.	0.50
05/05/20	KM	Call with D. Lundi, D. Fogel, R. Shamblen, V. Mancinelli and others (all Purdue) and J. DelConte, K. McCafferty and R. Sublett (all AlixPartners) re: finance transformation.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/05/20	KM	Analysis and hypothesis development re: finance re-engineering.	1.80
05/05/20	KM	Prepare finance re-engineering kick-off document.	1.60
05/05/20	KM	Analysis and presentation materials creation re: finance stages of maturity assessment.	1.40
05/05/20	NAS	Respond to question from PJT re: expiration dates of Mundipharma licensing agreements.	1.00
05/05/20	NAS	Review latest draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	1.00
05/05/20	NAS	Revise overview section of Mundipharma diligence report.	1.10
05/05/20	NAS	Build product-level metrics for Mundipharma Southeast Asia region in business plan model.	2.00
05/05/20	NAS	Provide update on Mundipharma business plan model to PJT.	0.80
05/05/20	NAS	Draft Mundipharma Germany commentary for Europe section of diligence report.	0.60
05/05/20	NAS	Review responses to Mundipharma Europe Q&A provided by Huron.	0.80
05/05/20	NAS	Call with N. Simon, G. Koch (both AlixPartners), J. Arsic, I. Mian (both PJT) re: latest drafts of Mundipharma model and report.	1.50
05/05/20	NAS	Revise Consumer Health section of Mundipharma business plan model.	1.00
05/05/20	NAS	Draft Mundipharma Consumer Health slides for diligence report.	1.90
05/06/20	NAS	Revise Consumer Health slides in Mundipharma diligence report.	2.70
05/06/20	NAS	Investigate mix of Mundipharma Consumer Health products in new data provided by management.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/06/20	NAS	Revise free cash flow section of Mundipharma model following discussion with PJT.	1.80
05/06/20	NAS	Draft Mundipharma Selling & Promotion slides for diligence report.	2.40
05/06/20	NAS	Revise model output reports to include 2018 and 2019 year-end estimated financials.	0.30
05/06/20	NAS	Review latest draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	0.50
05/06/20	NAS	Draft Mundipharma Medical Affairs slides for diligence report.	1.10
05/06/20	NAS	Draft Mundipharma G&A expense slides for diligence report.	1.90
05/06/20	IA	Review 4 and 12 week April consumption data for Avrio products and calculated market share to update Avrio dashboard.	1.70
05/06/20	IA	Participate in call with J. Lowne (Purdue), I. Arana, J. DelConte (both AlixPartners) and R. Schnitzler, J. Turner, J. Wang (all PJT) re: PHI scenario analysis.	0.80
05/06/20	KM	Interview with R. Shamblen (Purdue) re: Finance re-engineering opportunities.	1.10
05/06/20	KM	Analysis re: finance re-engineering.	0.20
05/06/20	KM	Interview with D. McGuire (Purdue) re: Finance re-engineering opportunities.	1.10
05/06/20	KM	Call with D. McGuire (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: client interview in connection with finance transformation.	0.50
05/06/20	KM	Call with K. McCafferty, R. Sublett (both AlixPartners), D. Fogel (Purdue) re: Rhodes Finance transformation daily update.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/06/20	KM	Analysis re: re-engineering opps.	0.60
05/06/20	JD	Review and provide comments on draft PJT analysis.	1.20
05/06/20	JD	Participate in call with J. Lowne (Purdue), I. Arana, J. DelConte (both AlixPartners) and R. Schnitzler, J. Turner, J. Wang (all PJT) re: PHI scenario analysis.	0.80
05/06/20	JD	Review draft analyses of stand alone Adhansia and Oncology FCF to provide to the UCC.	0.60
05/06/20	GJK	Review latest draft of Mundipharma diligence report with N. Simon, G. Koch (both AlixPartners).	0.50
05/06/20	GJK	Edits and updates to Mundipharma diligence report draft.	1.00
05/06/20	GJK	Draft biosimilar product category slides for Mundipharma interim diligence report .	3.00
05/06/20	GJK	Draft slides for Respiratory and Diabetes product category for Mundipharma interim diligence report .	3.00
05/06/20	GJK	Draft Oncology slides for Mundipharma interim diligence report .	3.00
05/06/20	GJK	Draft Other Ethical product slides for Mundipharma interim diligence report .	3.00
05/06/20	RDS	Call with K. McCafferty, R. Sublett (both AlixPartners), D. Fogel (Purdue) re: Rhodes Finance transformation daily update.	0.80
05/06/20	RDS	Call with D. McGuire (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: client interview in connection with finance transformation.	0.50
05/07/20	RDS	Call with J. Northington (Purdue), R. Sublett (partial attendance), K. McCafferty (both AlixPartners) re: initial customer interview for finance transformation.	0.40
05/07/20	RDS	Review latest pricing model for bid and provide commentary to D. Fogel (Purdue).	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/07/20	RDS	Prepare conclusions and subsequent notes coming out of interviews with R. Shamblen, D. McGuire and J. Northington (all Purdue).	1.40
05/07/20	GJK	Draft other Ethical product slides for Mundipharma interim diligence report (cont).	3.00
05/07/20	GJK	Edit key findings sections for Mundipharma interim diligence report .	3.00
05/07/20	GJK	Finalize draft of interim report general overview and key findings for PJT review and comments/edits for Mundipharma interim diligence report .	2.00
05/07/20	GJK	Mundipharma diligence reporting drafting - layout of adjusted section items for modeling by N. Simon (AlixPartners).	2.00
05/07/20	GJK	Call with N. Simon, G. Koch (both AlixPartners) re: Mundipharma adjusted case.	0.40
05/07/20	GJK	Series of calls with N Simon (AlixPartners) re: updates to draft Mundipharma diligence report.	1.20
05/07/20	GJK	Company and advisor status update and coordination call.	0.80
05/07/20	NAS	Test first two changes in adjustment case within Mundipharma business plan model.	0.20
05/07/20	JD	Call with J. Turner and T. Melvin (both PJT), E. Ruiz and J. Lowne (both Purdue) re: business segment cash flows.	0.60
05/07/20	JD	Call with J. Lowne (Purdue) re: business plan cash flows.	0.10
05/07/20	KM	Meeting with Rhodes supply chain team re. monthly S&OP process.	1.00
05/07/20	KM	Call with J. Northington (Purdue), R. Sublett (partial attendance), K. McCafferty (both AlixPartners) re: initial customer interview for finance transformation.	0.90
05/07/20	KM	Analysis re: Quality-related financial reporting	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		improvement opportunities.	
05/07/20	KM	Meeting with R. Shamblen (Purdue) re: cost allocations details for Bup-Nal and Hydrocodone.	0.50
05/07/20	KM	Analysis re: Bup-Nal cost accounting.	0.30
05/07/20	NAS	Build P&L slides for Mundipharma Oncology and Other Ethical segments.	0.50
05/07/20	NAS	Draft Mundipharma Other Ethical segment slides for diligence report.	1.40
05/07/20	NAS	Draft overview slide of data provided and limitations for Mundipharma diligence report.	1.00
05/07/20	NAS	Review latest draft of Mundipharma diligence report.	2.90
05/07/20	NAS	Call with N. Simon, G. Koch (both AlixPartners) re: Mundipharma adjusted case.	0.40
05/07/20	NAS	Set up Mundipharma model to incorporate adjusted case and calculate changes relative to base case.	1.90
05/07/20	NAS	Revise slides in consolidated Mundipharma diligence report.	2.20
05/08/20	NAS	Review all tabs in Mundipharma business plan model and current slides in diligence report for accuracy.	2.70
05/08/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: type and magnitude of adjustments to be made in adjusted case Mundipharma business plan model.	1.40
05/08/20	NAS	Incorporate initial adjustments in Mundipharma business plan model.	2.50
05/08/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: initial draft of Mundipharma adjusted case.	2.90
05/08/20	NAS	Revise adjustments in Mundipharma business plan model adjusted case following discussion with G. Koch (AlixPartners).	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/08/20	LJD	Call with R. Aleali (Purdue) re: audit committee meeting.	0.60
05/08/20	LJD	Review and comment on draft IAC report.	3.50
05/08/20	KM	Coordination of Rhodes partnership implementation effort.	0.80
05/08/20	RDS	Review and provide commentary for week 1 flash report of finance transformation strategy analysis.	0.40
05/08/20	RDS	Call with V. Mancinelli (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: customer interview.	1.20
05/08/20	KM	Analysis and edit re. flash report and update presentation finance re-engineering project.	1.90
05/08/20	KM	Call with V. Mancinelli (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: customer interview.	1.20
05/08/20	KM	Analysis and follow up re: finance interviews with BU leaders.	1.40
05/08/20	KM	Call with D. Fogel (Purdue) re: data collection.	0.10
05/08/20	KM	Analysis and hypothesis development re: finance re-engineering.	0.90
05/08/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: finance re-engineering opportunities.	1.50
05/08/20	KM	Research and planning re: finance re-engineering opportunities.	0.40
05/08/20	JD	Review preliminary professional fee estimates for company month end accruals.	0.50
05/08/20	JD	Correspondence with R. Aleali (Purdue) and S. Lemack (AlixPartners) re: publicly filed financial reports.	0.30
05/08/20	JD	Review updated comments from J. Lowne (Purdue) re: AHC diligence requests.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/08/20	JD	Review financial analysis of potential licensing agreement.	0.70
05/08/20	JD	Review correspondence from R. Aleali (Purdue) and A. DePalma (AlixPartners) re: UCC diligence response.	0.30
05/08/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: type and magnitude of adjustments to be made in adjusted case Mundipharma business plan model.	1.40
05/08/20	GJK	Create key adjustments impact analysis for Mundipharma interim diligence report .	3.00
05/08/20	GJK	Create key adjustments impact analysis on volume drivers for Mundipharma interim diligence report .	1.00
05/08/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: initial draft of Mundipharma adjusted case.	2.90
05/08/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: finance re-engineering opportunities.	1.50
05/09/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: walk through specific adjustments to base case Mundipharma business model.	0.40
05/09/20	GJK	Edit key adjustments impact slides for Mundipharma interim diligence report .	3.00
05/09/20	GJK	Review key adjustments and reduce impact of certain items and analysis of EBIT impact; variance review.	3.50
05/09/20	LJD	Review documents and correspondence from creditors.	0.90
05/09/20	LJD	Review discussion docs for creditor meetings.	0.90
05/09/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: walk through specific adjustments to base case Mundipharma business model.	0.40
05/09/20	NAS	Incorporate revisions to Mundipharma adjusted case following correspondence with G. Koch (AlixPartners).	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/09/20	NAS	Respond to question from PJT re: Mundipharma capital structure.	0.80
05/09/20	NAS	Review latest Mundipharma adjusted case following revisions to magnitude of adjustments.	0.30
05/10/20	NAS	Provide Mundipharma adjusted case model to PJT and corresponding overview.	0.50
05/10/20	GJK	Tie out risk adjustments from analysis.	2.00
05/10/20	GJK	Create risk adjustment overview slides for Mundipharma interim diligence report.	2.00
05/10/20	GJK	Draft risk adjustment slides for Mundipharma interim diligence report on impact of changes in OxyContin prices and impact of SG&A.	2.00
05/10/20	GJK	Analyze FTEs related to S&P in China and draft related slide.	1.00
05/11/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma adjusted case presentation and discuss latest developments in diligence process.	1.00
05/11/20	GJK	Call with I. McClatchey (Norton Rose) re: Mundipharma board process.	0.70
05/11/20	GJK	Follow up call with J. Turner (PJT) re: Deutsche Bank.	0.20
05/11/20	GJK	Coordinate on plan for open issues in Mundipharma diligence.	2.00
05/11/20	GJK	Revised risk adjustment slides for Mundipharma interim diligence report.	3.00
05/11/20	GJK	Follow up analysis on risk adjustment impact for Mundipharma interim diligence report.	2.00
05/11/20	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC diligence.	0.20
05/11/20	JD	Call with R. Aleali (Purdue) re: creditor discussions and	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		board meeting agenda.	
05/11/20	JD	Review initial draft IAC diligence presentation.	1.50
05/11/20	JD	Review flash reports provided to date per company request.	0.50
05/11/20	JD	Review recent Project Catalyst letter of intent.	0.20
05/11/20	KM	Analysis re: time allocation tracking for Finance.	0.70
05/11/20	KM	Analysis re: Maraviroc development / regulatory cost allocations.	0.80
05/11/20	KM	Call with D. Fogel (Purdue) re: cost allocation analysis for Wilson e.g. Maraviroc.	0.50
05/11/20	KM	Prepare slide re: re-engineering meeting with D. Lundie (Purdue).	1.00
05/11/20	KM	Meeting with R. Shamblen (Purdue) re: cost allocations details for Bup-Nal and Hydrocodone.	0.50
05/11/20	KM	Analysis re: finance activity by significant contribution.	1.20
05/11/20	KM	Analysis re: unabsorbed overhead for UCC.	0.80
05/11/20	NAS	Review initial draft of slides related to Mundipharma adjusted case.	2.10
05/11/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma adjusted case presentation and discuss latest developments in diligence process.	1.00
05/11/20	NAS	Correspondence with PJT re: latest draft of Mundipharma diligence report.	0.20
05/11/20	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC diligence.	0.20
05/11/20	IA	Update side by side cost assumptions to reflect comments received from Purdue management.	1.20
05/11/20	IA	Review and edit April business plan presentation to be	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		shared on non PEO basis with creditors, for review by management and legal.	
05/11/20	IA	Draft summary of changes to April business plan presentation to be shared on non PEO basis with creditors, for review by management and legal.	0.90
05/11/20	IA	Provide comments to latest version of side by side requested by creditors.	0.50
05/11/20	LJD	Review correspondence re: Mundipharma sales process.	0.40
05/11/20	RDS	Review variable pricing finance model for cross-functional work within Rhodes organization - variabralize cost structure for true outside costs.	0.60
05/11/20	RDS	Changes to insourcing model for potential API partnership opportunities.	1.40
05/11/20	RDS	Review M&A document and transaction impact on current work streams, prepare materials for call with Rhodes CFO.	0.60
05/11/20	RDS	Review financial reporting requirements at Rhodes entities and classify along initial order of importance.	0.80
05/11/20	ADD	Extract and organize data to review and analyze liabilities subject to compromise.	1.50
05/12/20	RDS	Prepare for call with D. Fogel (Purdue) re: review CPP information and strategic options for Project Catalyst.	0.20
05/12/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) to prepare analytics for Project Catalyst and monthly board reporting updates.	1.30
05/12/20	RDS	Contextualize Project Catalyst offers in a presentation for RELT.	0.90
05/12/20	RDS	Meeting with D. Fogel, D. Lundie (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst and restructuring.	
05/12/20	RDS	Meeting with R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: potential strategic partnerships.	1.30
05/12/20	LJD	Review revised UCC deck and comment.	0.80
05/12/20	LJD	Call with PJT.	0.40
05/12/20	LJD	Call with C. Landau, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT) and L. Donahue, J. DelConte, I. Arana (all AlixPartners) re: updated side by side re: overview presentation and assumptions.	1.10
05/12/20	IA	Call with C. Landau, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT) and L. Donahue, J. DelConte, I. Arana (all AlixPartners) re: updated side by side re: overview presentation and assumptions.	1.10
05/12/20	IA	Review updated March monthly flash report to be submitted for approvals.	1.30
05/12/20	NAS	Review latest draft of Mundi report adjusted case slides.	1.10
05/12/20	NAS	Test potential revisions to adjusted case of Mundipharma business plan model.	0.70
05/12/20	NAS	Review Mundipharma LAM diligence Q&A provided by Huron.	0.50
05/12/20	NAS	Call with M. Diaz, B. Bromberg (both FTI) and N. Simon, G. Koch (both AlixPartners) re: Mundipharma diligence process and key areas not responded to.	0.80
05/12/20	NAS	Call with J. Arsic (PJT) re: current status of Mundipharma diligence report and remaining open questions.	0.40
05/12/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to coordinate on best approach for Mundi diligence process	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/12/20	KM	and provide update on PJT analysis for report.	
05/12/20	KM	Call with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) to prepare analytics for Project Catalyst and monthly board reporting updates.	1.30
05/12/20	KM	Analysis re: Project Catalyst analysis preparation.	0.20
05/12/20	KM	Meeting with D. Fogel, D. Lundie (both Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst and restructuring.	1.80
05/12/20	KM	Analysis re: Rhodes combined headcount as of March 2020.	0.70
05/12/20	KM	Meeting with R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: potential strategic partnerships.	1.30
05/12/20	JD	Call with R. Schnitzler, J. Turner (both PJT), R. Aleali and J. Doyle (both Purdue) re: BD opportunity.	0.70
05/12/20	JD	Call with J. DelConte, G. Koch (both AlixPartners) re: IAC diligence update.	0.30
05/12/20	JD	Review draft proposed redactions of the business plan creditor presentation to create a non-PEO version from I. Arana (AlixPartners).	0.60
05/12/20	JD	Review historical 10 year R&D spend in response to open diligence question from the AHC.	0.50
05/12/20	JD	Review and provide comments on the updated side by side analysis.	0.90
05/12/20	JD	Review board slides re: Rhodes BD opportunity.	0.60
05/12/20	JD	Call with C. Landau, M. Kesselman, J. Lowne (all Purdue), J. O'Connell, J. Turner, R. Schnitzler (all PJT) and L. Donahue, J. DelConte, I. Arana (all AlixPartners) re: updated side by side re: overview presentation and	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		assumptions.	
05/12/20	GJK	Review of Mundipharma selected responses to LAM region questions.	3.00
05/12/20	GJK	Follow up analysis on SG&A spend for Mundipharma interim diligence report.	2.00
05/12/20	GJK	Review open items for Mundipharma interim diligence report.	2.00
05/12/20	GJK	Coordinate and plan on open items for LAM Region responses.	2.00
05/12/20	GJK	Call with M. Diaz, B. Bromberg (both FTI) and N. Simon, G. Koch (both AlixPartners) re: Mundipharma diligence process and key areas not responded to.	0.80
05/12/20	GJK	Call with J. DelConte, G. Koch (both AlixPartners) re: IAC diligence update.	0.30
05/12/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to coordinate on best approach for Mundi diligence process and provide update on PJT analysis for report.	0.70
05/13/20	GJK	Discussion with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma report.	0.40
05/13/20	GJK	Call with KPMG, G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors re: findings from IAC tax workstream.	1.40
05/13/20	GJK	Update risk adjustment slides for Mundipharma interim diligence report based on updated Mundipharma responses.	3.00
05/13/20	GJK	Review of Mundipharma selected responses to Europe region questions.	3.00
05/13/20	GJK	Add in product x volume for 2019 for comparative analysis.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/13/20	JD	Review and provide comments on draft sales reports.	0.40
05/13/20	JD	Initial review of emergence structure analysis from Davis Polk.	1.30
05/13/20	JD	Call with J. Lowne (Purdue) re: UCC scenario analysis.	0.20
05/13/20	JD	Participate in call with I. Arana, J. DelConte (both AlixPartners), R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), and R. Aleali (Purdue). re: business development deal for Rhodes.	0.70
05/13/20	JD	Call with D. Lundie, C. Landau, M. Kesselman, J. Lowne and others (Purdue), K. McCafferty, J. DelConte, R. Sublett (AlixPartners) re: Project Catalyst observations, recommendations and conclusions.	1.00
05/13/20	JD	Review draft presentation re: Project Catalyst in advance of call with the team.	0.80
05/13/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst.	0.50
05/13/20	JD	Review updated scenarios for UCC scenario analysis and provide comments.	0.60
05/13/20	JD	Review latest weekly NPA data.	0.30
05/13/20	KM	Analysis of sourcing options.	1.00
05/13/20	KM	Analysis and slide preparation re: Project Catalyst 5/13 presentation to Landau/Lowne/Kesselman.	0.90
05/13/20	KM	Meeting with R. Shamblen and D. Fogel (both Purdue) re: potential offer.	0.40
05/13/20	KM	Analysis re: potential insourcing partnership.	0.60
05/13/20	KM	Analysis re: potential insourcing partnership (continued).	1.30
05/13/20	KM	Call with D. Fogel, D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: updated Project Catalyst comparison presentations.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/13/20	KM	Analysis and slide preparation re: Project Catalyst 5/13 presentation to Landau/Lowne/Kesselman.	1.40
05/13/20	KM	Edit presentation re: Project Catalyst 5/13 presentation to Landau/Lowne/Kesselman.	0.40
05/13/20	KM	Call with D. Lundie, C. Landau, M. Kesselman, J. Lowne and others (Purdue), K. McCafferty, J. DelConte, R. Sublett (AlixPartners) re: Project Catalyst observations, recommendations and conclusions.	1.00
05/13/20	KM	Next steps planning for Project Catalyst.	0.20
05/13/20	NAS	Review latest draft of diligence requests from Advisor Group to Mundipharma.	0.60
05/13/20	NAS	Review latest draft of Mundipharma diligence report and comment for revisions where necessary.	3.20
05/13/20	NAS	Review KPMG materials in advance of IAC tax discussion.	0.40
05/13/20	NAS	Call with KPMG, G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors re: findings from IAC tax workstream.	1.40
05/13/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma report.	0.40
05/13/20	IA	Participate in call with I. Arana, J. DelConte (both AlixPartners), R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), and R. Aleali (Purdue). re: business development deal for Rhodes.	0.70
05/13/20	IA	Finalize non PEO draft of April business plan presentation requested by committees and submitted for review by PJT and Purdue management.	1.80
05/13/20	IA	Update PHI scenario costs to incorporate Purdue management's comments, updated summaries and submitted for review by PJT and J. Lowne (Purdue).	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/13/20	LJD	Review and comment on revised side by side analysis.	0.70
05/13/20	LJD	Call with PJT re: scenarios for UCC and split of AlixPartners work versus PJT work.	0.40
05/13/20	RDS	Assemble materials re: Project Catalyst with J. Lowne (Purdue) according to input from D. Lundie & D. Fogel (Purdue).	1.00
05/13/20	RDS	Assemble presentation to compare metrics for various Project Catalyst proposals.	1.90
05/13/20	RDS	Call with D. Fogel, D. Lundie (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: updated Project Catalyst comparison presentations.	0.50
05/13/20	RDS	Turn comments from D. Lundie (Purdue), with regard to the Project Catalyst presentation to senior PPLP management.	0.60
05/13/20	RDS	Call with D. Lundie, C. Landau, M. Kesselman, J. Lowne and others (Purdue), K. McCafferty, J. DelConte, R. Sublett (AlixPartners) re: Project Catalyst observations, recommendations and conclusions.	1.00
05/14/20	RDS	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, R. Shamblan, J. Doyle, R. Aleali, D. Fogel (all Purdue), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst and approve next steps for the project.	0.70
05/14/20	RDS	Correspondence and coordination with Windsor advisors in order to prepare materials in support of Project Catalyst.	0.40
05/14/20	LJD	Prepare for and attend call with J. DelConte, L. Donahue (both AlixPartners), M. Huebner, C. Robertson, T. Graulich (all Davis Polk), J. Turner, T. Coleman, J. O'Connell (all PJT), C. Landau, J. Lowne, M. Kesselman,	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/14/20	LJD	R. Aleali (all Purdue) re: case progress and go forward planning.	
05/14/20	LJD	Participate in PPI Board call with J. DelConte, L. Donahue (both AlixPartners), J. Lowne, C. Landau, M. Kesselman (all Purdue), J. Turner (PJT), M. Huebner, C. Robertson (both Davis Polk), J. Bragg (Skadden)re: Audit Committee meeting.	1.50
05/14/20	LJD	Debrief call with J. Dubel - board member.	0.40
05/14/20	LJD	Review and comment on revised side by side presentation.	0.60
05/14/20	MH	Discussion with M. Hartley, S. Lemack (both AlixPartners) re: indemnification cost approval process.	0.60
05/14/20	IA	Follow up on approvals for non PEO business plan presentation.	0.40
05/14/20	IA	Review updated side by side presentation updated per request received from UCC.	1.30
05/14/20	IA	Gather comments and drafts responses to UCC questions on status of reporting items.	1.10
05/14/20	IA	Update Avrio dashboard to incorporate edits from Avrio management.	0.40
05/14/20	NAS	Review second half of Mundipharma diligence report draft and note comments where necessary.	1.90
05/14/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma report and discuss revisions where necessary.	1.30
05/14/20	NAS	Review first half of Mundipharma diligence report draft and note comments where applicable.	2.00
05/14/20	NAS	Incorporate revisions to latest draft of Mundipharma diligence report following discussion with G. Koch	2.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(AlixPartners).	
05/14/20	KM	Analysis re: Project Catalyst insourcing opportunity valuation.	0.70
05/14/20	KM	Prepare for and attend call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, R. Shamblan, J. Doyle, R. Aleali, D. Fogel (all Purdue), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst and approve next steps for the project.	1.00
05/14/20	KM	Data review and analysis re: finance restructuring.	1.20
05/14/20	KM	Data consolidation re: RALP headcount.	2.90
05/14/20	KM	Analysis and reconciliation re: RALP organizational synergies.	1.20
05/14/20	JD	Review update from G. Koch (AlixPartners) re: IAC diligence process prior to update call.	0.30
05/14/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners), M. Huebner, C. Robertson, T. Graulich (all Davis Polk), J. Turner, T. Coleman, J. O'Connell (all PJT), C. Landau, J. Lowne, M. Kesselman, R. Aleali (all Purdue) re: case progress and go forward planning.	1.00
05/14/20	JD	Participate in PPI Board call with J. DelConte, L. Donahue (both AlixPartners), J. Lowne, C. Landau, M. Kesselman (all Purdue), J. Turner (PJT), M. Huebner, C. Robertson (both Davis Polk), J. Bragg (Skadden)re: Audit Committee meeting.	1.50
05/14/20	JD	Review due diligence request list from FTI. Review materials provided to date in response to BP questions.	1.30
05/14/20	JD	Review branded P&L by segment analysis in response to open business plan diligence questions.	0.40
05/14/20	JD	Review updated UCC scenario presentation for management comments.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/14/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst and other go forward planning.	1.20
05/14/20	JD	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), J. Lowne, D. Lundie, R. Shamblan, J. Doyle, R. Aleali, D. Fogel (all Purdue), R. Schnitzler, J. Turner (both PJT) re: Project Catalyst and approve next steps for the project.	0.70
05/14/20	JD	Review comments and responses to open diligence requests from Province.	0.50
05/14/20	JD	Review latest draft Project Catalyst term sheets.	1.00
05/14/20	GJK	Draft Europe region country slides for Mundipharma interim diligence report.	3.50
05/14/20	GJK	Draft LAM region country slides for Mundipharma interim diligence report.	3.50
05/14/20	GJK	Draft LAM region country slides for Mundipharma interim diligence report (cont).	3.50
05/14/20	GJK	Review/comments/edits to N. Simon edits of Mundipharma interim diligence report.	1.50
05/14/20	GJK	Mundipharma diligence update call with J Turner (PJT), G. Koch and J. DelConte (both AlixPartners).	0.30
05/14/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma report and discuss revisions where necessary.	1.30
05/14/20	JD	Mundipharma diligence update call with J Turner (PJT), G. Koch and J. DelConte (both AlixPartners).	0.30
05/15/20	GJK	Edit and update to Mundipharma diligence report draft.	2.40
05/15/20	GJK	Walk through for key findings for current Mundipharma interim diligence report.	1.00
05/15/20	JD	Call with R. Aleali (Purdue) re: UCC scenarios.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/15/20	JD	Call with S. Lemack (Purdue) re: diligence items and monthly reporting.	0.20
05/15/20	JD	Call with J. Bragg (Skadden), S. Birnbaum (Dechert), R. Aleali, C. George (both Purdue), J. Turner (PJT) J. DelConte and L. Donahue (both AlixPartners) re: monitor findings.	0.50
05/15/20	JD	Review and pull MOR from Insys for J. Lowne (Purdue).	0.20
05/15/20	JD	Review analysis of severance by employee for Purdue.	0.50
05/15/20	JD	Call with R. Aleali (Purdue) re: monitor report.	0.20
05/15/20	JD	Call with C. Robertson, E. Vonnegut (both Davis Polk), R. Schnitzler and J. Turner (all PJT) J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst.	0.70
05/15/20	KM	Analysis re: finance reporting and activity analysis.	1.30
05/15/20	KM	Analysis re: Quality organization restructuring mapping to roster/salary data.	1.60
05/15/20	KM	Analysis re: Supply Chain organization restructuring mapping to roster/salary data.	0.80
05/15/20	KM	Call with J. Northington (Purdue) re: Quality organization restructuring mapping to roster/salary data.	0.70
05/15/20	KM	Analysis and Slides creation re: recommended Supply Chain organization.	1.30
05/15/20	KM	Analysis re: organizational restructuring proposal from Big 4.	0.60
05/15/20	KM	Meeting with R. Haberlin (Purdue) re: finance activity and reporting.	0.50
05/15/20	KM	Meeting with W. DiNicola (Purdue) re: finance activity and reporting.	0.80
05/15/20	KM	Analysis re: finance activity.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/15/20	KM	Meeting with J. Carlisle (Purdue) re: finance activity and reporting.	1.00
05/15/20	KM	Call with C. Robertson, E. Vonnegut (both Davis Polk), R. Schnitzler and J. Turner (all PJT) J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst.	0.70
05/15/20	NAS	Revise latest draft of Mundipharma diligence report following discussion with G. Koch (AlixPartners).	3.10
05/15/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma diligence report.	0.60
05/15/20	NAS	Plan Mundipharma diligence priorities for following week.	0.50
05/15/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: latest draft of Mundipharma diligence report.	0.60
05/15/20	IA	Calculate average severance per employee for Purdue, as requested by Purdue finance team for scenario modeling.	0.70
05/15/20	IA	Follow up on approvals and finalize non PEO version of business plan presentation, as requested by the committees.	1.10
05/15/20	LJD	Review side by side UCC presentation.	0.40
05/15/20	LJD	Prepare for and attend call with J. Bragg (Skadden), S. Birnbaum (Dechert), R. Aleali, C. George (both Purdue), J. Turner (PJT) J. DelConte and L. Donahue (both AlixPartners) re: monitor findings.	0.60
05/15/20	RDS	Call with E. Vonnegut, C. Robertson (DPW), J. DelConte, K. McCafferty (AlixPartners), J. Turner, R. Schnitzler, T. Melvin (PJT) re: Project Catalyst time line and term sheet.	0.70
05/15/20	RDS	Review proposed supply chain organizational restructuring for Rhodes / Avrio.	0.90
05/16/20	RDS	Review Rhodes Pharma generic pharmaceutical valuation analysis and impact on restructuring plans for the cost	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/18/20	RDS	structure.	
05/18/20	RDS	Assemble headcount reorganization for Rhodes R&D organization, including quality, supply chain, pharm tech and prepare presentation materials.	1.40
05/18/20	RDS	Complete pivot and other data analysis on finance team survey data for time allocations and report preparation to align strategy to proposed reorganization.	1.80
05/18/20	RDS	Complete weekly update discussion materials for Rhodes CFO discussion.	0.80
05/18/20	GJK	Analysis of key open items including 2019 actual to YEE variance.	3.00
05/18/20	GJK	Review Mundipharma balance sheets and cash forecast from YEE to assess what can be included in interim report.	3.00
05/18/20	JD	Call with C. Robertson (Davis Polk) re: open process questions.	0.20
05/18/20	JD	Call with C. Robertson (Davis Polk) and R. Aleali (Purdue) re: Project Catalyst.	0.70
05/18/20	JD	Review Butrans Mexico royalty details.	0.50
05/18/20	JD	Review latest Project Catalyst update and legal correspondence.	0.60
05/18/20	JD	Review and provide comments on updated March flash report before sending around for approvals.	1.20
05/18/20	JD	Review details of unpaid liabilities and footnote in the audited financials.	0.40
05/19/20	JD	Call with J. Lowne (Purdue) re: latest side by side deck.	0.20
05/19/20	JD	Call with J. DelConte and A. DePalma (both AlixPartners) re: diligence process and go forward work plan.	0.40
05/19/20	JD	Review and provide comments on presentation created in	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		response to VT AG requests.	
05/19/20	JD	Review latest diligence tracker for IAC diligence questions. Review correspondence re: diligence process.	0.70
05/19/20	JD	Review latest IAC diligence report in conjunction with open diligence requests.	0.80
05/19/20	KM	Call with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: weekly finance and R&D turnaround plans.	2.10
05/19/20	KM	Call with N. Davis (Purdue), K. McCafferty, R. Sublett (both AlixPartners) to reconcile headcount estimates to latest items and cost out assumptions.	0.80
05/19/20	KM	Analysis re: organization restructuring.	0.50
05/19/20	KM	Ideation and activity mapping re: RT R&D organization strawman.	1.20
05/19/20	KM	Analysis re: RT R&D organization strawman.	1.20
05/19/20	KM	Create slide re: RT R&D organization strawman.	0.80
05/19/20	KM	Meeting with D. Lundie, D. Fogel (both Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: organization strawman for Rhodes.	1.60
05/19/20	KM	Analysis re: proposed finance org structure.	0.80
05/19/20	GJK	Create draft analysis for product COGs for Mundipharma diligence.	2.00
05/19/20	GJK	Review back up slides re: Mundipharma VDD for potential inclusion in report.	2.00
05/19/20	GJK	Review Consumer Health VDD for potential inclusions/back up for Mundipharma interim diligence report.	1.00
05/19/20	RDS	Call with N. Davis (Purdue), K. McCafferty, R. Sublett (both AlixPartners) to reconcile headcount estimates to	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/19/20	RDS	latest items and cost out assumptions.	
05/19/20	RDS	Layout approach for next steps to the reorganization of the R&D organization and correspondence with M. Sisodia, D. Ebere, K. Kolar and R. TheBeau (all Purdue) re: the same.	0.70
05/19/20	RDS	Review R&D org structure and prepare presentation slides to discuss with management.	0.90
05/19/20	RDS	Meeting with D. Lundie, D. Fogel (both Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: organization strawman for Rhodes.	1.60
05/19/20	RDS	Assemble recommendation slides for finance transformation headcount organization.	0.70
05/19/20	RDS	Call with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: weekly finance and R&D turnaround plans.	2.10
05/19/20	RDS	Assemble presentation materials for Rhodes Pharma analysis.	0.60
05/19/20	ADD	Call with J. DelConte and A. DePalma (both AlixPartners) re: diligence process and go forward work plan.	0.40
05/20/20	RDS	Assemble organizational effectiveness materials and prepare for interviews with company representatives re: the same.	2.70
05/20/20	RDS	Review and reconciliation of quality org structure to current headcount file.	1.20
05/20/20	RDS	Prepare question list for M. Sisodia (Purdue) interview.	0.30
05/20/20	RDS	Meeting with M. Sisodia (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: business development process.	1.10
05/20/20	GJK	Review Sales and Promotion spend 2017-2018 in VDD for	2.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Mundipharma back up.	
05/20/20	GJK	Email J. Turner (PJT) re: FTI/Kramer Levine next steps for diligence requests for Mundipharma.	0.20
05/20/20	GJK	Email J. DelConte (AlixPartners) re: FTI/Kramer Levine next steps for diligence requests for Mundipharma.	0.20
05/20/20	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC update.	0.20
05/20/20	NAS	Review latest Mundipharma diligence documents provided and track outstanding requests.	0.70
05/20/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Mundipharma diligence priorities for remainder of week.	0.30
05/20/20	NAS	Call with G. Koch, N. Simon (both AlixPartners), M. Diaz, B. Bromberg (both FTI) re: outstanding Mundipharma diligence requests and best approach moving forward.	0.40
05/20/20	NAS	Correspondence with J. Arsic (PJT) re: latest draft of Mundipharma diligence report.	0.20
05/20/20	IA	Run accounts payable reports for payment review and release process.	0.60
05/20/20	IA	Draft responses to comments received from third party analytics firm on requested consent to share Avrio product information.	1.60
05/20/20	KM	Next phase planning for Rhodes R&D and Finance initiatives.	0.50
05/20/20	KM	Analysis re: commercial organization restructuring.	1.00
05/20/20	KM	Analysis re: RALP headcount mapping.	1.40
05/20/20	KM	Analysis and report creation re Rhodes organization restructuring for Rhodes Tech R&D.	1.80
05/20/20	KM	Analysis re: Quality organization proposed restructuring reconciliation.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/20/20	KM	Meeting with M. Sisoda (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: business development process.	1.10
05/20/20	KM	Analysis re: recommended Rhodes Pharm Product Development org structure.	1.00
05/20/20	KM	Analysis and slide creation re: recommended Rhodes Pharm Product Development org structure.	1.50
05/20/20	KM	Analysis re: Finance re-engineering activity mapping and preliminary opportunity development.	1.10
05/20/20	JD	Call with J. Lowne (Purdue) re: opioid only scenario.	0.40
05/20/20	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC update.	0.20
05/20/20	JD	Correspondence with R. Brown (Purdue) re: updated professional fee forecasts and spending to date.	1.30
05/20/20	JD	Review forms and materials collected in relation to Bureau of Economic Analysis forms to be completed and filed.	1.50
05/20/20	JD	Review and provide comments re: weekly agenda.	0.40
05/20/20	JD	Update professional fee tracker and 2020 forecast.	0.80
05/20/20	JD	Review correspondence from I. Arana (AlixPartners), R. Aleali and J. Tran (both Purdue) re: sharing Nielsen data.	0.60
05/20/20	JD	Review questions from Duff & Phelps and potential responses re: public health initiatives.	1.00
05/20/20	JD	Review and provide comments on updated buyers log draft.	0.20
05/20/20	JD	Review correspondence from E. Ruiz and J. Lowne (both Purdue) re: Duff & Phelps questions.	0.30
05/20/20	GJK	Draft follow up email re: Mundipharma outstanding info request items sent to Huron and Advisor group.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/20/20	GJK	Call with G. Koch, N. Simon (both AlixPartners), M. Diaz, B. Bromberg (both FTI) re: outstanding Mundipharma diligence requests and best approach moving forward.	0.40
05/20/20	GJK	Email C. Robertson (Davis Polk) re: FTI/Kramer Levine next steps for diligence requests for Mundipharma.	0.20
05/20/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to prep for FTI Mundipharma call.	0.30
05/21/20	JD	Prepare for weekly update call.	0.30
05/21/20	JD	Review draft Project Catalyst term sheets.	2.50
05/21/20	JD	Call with J. Turner and R. Schnitzler (both PJT), J. Lowne and E. Ruiz (both Purdue) re: opioid only scenario.	0.80
05/21/20	JD	Call with I. Arana, J. DelConte (both AlixPartners), R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), and R. Aleali (Purdue). re: business development deal for Rhodes.	0.50
05/21/20	JD	Review correspondence from R. Silbert and R. Aleali (both Purdue) re: open AG requests.	0.50
05/21/20	JD	Review updated draft responses re: Nielsen data sharing.	0.40
05/21/20	JD	Call with J. Lowne (Purdue) re: financials.	0.20
05/21/20	KM	Call with N. Davis (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: May dashboard update.	1.30
05/21/20	KM	Analysis re: RALP salary and wages by level.	1.70
05/21/20	KM	Meeting with R. Thebeau (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: commercial operations org opportunities and SWOT.	1.00
05/21/20	KM	Meeting with D. Ebere (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: product development pipeline and update processes.	1.00
05/21/20	KM	Analysis re: RALP supervisory / management layers and	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		compensation.	
05/21/20	KM	Analysis re: Rhodes Tech org reduction opportunities.	1.70
05/21/20	IA	Call with I. Arana, J. DelConte (both AlixPartners), R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), and R. Aleali (Purdue). re: business development deal for Rhodes.	0.50
05/21/20	IA	Review third party comments to request for consent to share Avrio product data with the committees and update slides to reflect requested edits.	1.40
05/21/20	IA	Follow up with management on database and report details to be sent to third party as part of commentary on requested consent to share data with committees.	0.80
05/21/20	IA	Update 2021 and 2022 LTRP payment estimates to show 2017 performance breakout and payment details by level (VP and above versus below VP).	2.90
05/21/20	IA	Draft summary and notes to be sent to Davis Polk and Willis Towers Watson, summarizing requested data on 2021 and 2022 LTRP estimated payments.	1.40
05/21/20	GJK	Review of Mundipharma 2019 board decks for Mundipharma interim diligence report potential back up.	3.00
05/21/20	RDS	Call with N. Davis (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: May dashboard update.	1.30
05/21/20	RDS	Review BD notes and prepare conclusions for pipeline process improvements for generic product development.	0.80
05/21/20	RDS	Analysis of data for recommendations re: future organizational structure.	3.10
05/21/20	RDS	Meeting with R. Thebeau (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: commercial operations org opportunities and SWOT.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/21/20	RDS	Meeting with D. Ebere (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: product development pipeline and update processes.	1.00
05/22/20	RDS	Assemble interview notes into management presentation on recommendations for organizational and process restructuring of Rhodes business.	2.40
05/22/20	RDS	Call with R. Schnitzler (PJT), J. DelConte, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.40
05/22/20	RDS	Assemble slides to outline rationale for supply chain organization.	0.70
05/22/20	RDS	Organize conclusions from R&D process improvement interviews into presentation of recommendations.	2.10
05/22/20	RDS	Meeting with K. Kolar (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma R&D org opportunities and SWOT.	1.00
05/22/20	GJK	Plan for updates to Mundipharma model and interim report based on Huron's indication of updated key information to be provided.	1.50
05/22/20	NAS	Research question posed by FTI re: Mundipharma tax workstream.	0.10
05/22/20	NAS	Respond to question from J. Arsic (PJT) re: balance sheet valuation of Mundipharma joint ventures.	0.50
05/22/20	KM	Next phase planning for Rhodes R&D and Finance initiatives.	0.50
05/22/20	KM	Analysis and slide creation re: recommendations for the RELT meeting 5/27.	1.90
05/22/20	KM	Analysis and slide creation re: Rhodes Tech re-org and re-engineering.	0.60
05/22/20	KM	Plan for Project Catalyst implementation.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/22/20	KM	Analysis and slide creation re: Rhodes supply chain re-org and re-engineering.	1.50
05/22/20	KM	Analysis and report creation re Rhodes organization restructuring for Rhodes Tech R&D.	1.50
05/22/20	KM	Meeting with K. Kolar (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes Pharma R&D org opportunities and SWOT.	1.00
05/22/20	KM	Advisors call with R. Schnitzler (PJT), R. Sublett and J. DelConte (AlixPartners) re: Project Catalyst.	0.40
05/22/20	JD	Call with R. Schnitzler (PJT), J. DelConte, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.40
05/22/20	JD	Call with R. Aleali (Purdue) re: deals.	0.40
05/22/20	JD	Call with J. Lowne (Purdue) re: go forward planning.	0.20
05/22/20	JD	Review and provide comments on detailed opioid only business forecast assumptions.	1.00
05/22/20	JD	Review and provide comments on draft slides for Board presentation re: BD deal.	1.10
05/22/20	JD	Call with J. Turner (PJT) re: deal process.	0.20
05/22/20	JD	Review correspondence from C. DiStefano (Purdue), E. Vonnegut (Davis Polk) and I. Arana (AlixPartners) re: bonus programs.	0.50
05/22/20	JD	Review correspondence and responses from R. Aleali and R. Silbert (both Purdue) re: AG requests.	0.40
05/23/20	KM	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, D. Lundie (both Purdue) and J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst process management.	0.70
05/23/20	JD	Correspondence with Davis Polk re: Project Catalyst.	0.30
05/23/20	JD	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, D.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Lundie (both Purdue) and J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst process management.	
05/23/20	RDS	Call with J. Turner, R. Schnitzler (both PJT), J. Lowne, D. Lundie (both Purdue) and J. DelConte, R. Sublett, K. McCafferty (all AlixPartners) re: Project Catalyst process management.	0.70
05/24/20	RDS	Correspondence with D. Fogel, D. Lundie (both Purdue) re: ongoing workstreams.	0.60
05/25/20	RDS	Layout sales process timeline, approval steps to close and DD dataroom index	1.60
05/26/20	RDS	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), D. Lundie, J. Doyle, R. Shambren, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. Turner, R. Schnitzler (both PJT), M. Florence, M. Gibson, J. Bragg (all Skadden), C. Robertson (Davis Polk) re: Project Catalyst	2.00
05/26/20	RDS	Review org structures before call with D. Fogel (Purdue) re: org structures.	2.20
05/26/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: org structure for BIG 4 meeting 5/27.	1.40
05/26/20	RDS	Call with R. Sublett, J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: PMO and data room index for Project Catalyst.	0.60
05/26/20	RDS	Build presentation for org structure discussion with D. Lundie (Purdue) incorporating commentary from D. Fogel (Purdue).	1.50
05/26/20	ADD	Advisors meeting with J. DelConte, A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst.	
05/26/20	ADD	Call with R. Sublett, J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: PMO and data room index for Project Catalyst.	0.60
05/26/20	RDS	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst action items.	0.70
05/26/20	RDS	Meeting with D. Fogel (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: discussion of organization restructuring options.	1.10
05/26/20	RDS	Advisors meeting with J. DelConte, A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.70
05/26/20	KM	Call with R. Sublett, J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: PMO and data room index for Project Catalyst.	0.60
05/26/20	KM	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. Turner, R. Schnitzler (both PJT), M. Florence, M. Gibson, J. Bragg (all Skadden), C. Robertson (Davis Polk) re: Project Catalyst	2.00
05/26/20	KM	Edit deck and preparation re: org structure for BIG 4 meeting 5/27.	1.30
05/26/20	KM	Analysis and slide creation re: discussion of organization restructuring options.	0.50
05/26/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: Project Catalyst action items.	0.70
05/26/20	KM	Meeting with D. Fogel (Purdue), K. McCafferty, R. Sublett	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(both AlixPartners) re: discussion of organization restructuring options.	
05/26/20	KM	Analysis and reconciliation re: phase 1 and phase 2 restructuring options versus Jan 30 Board budget.	1.40
05/26/20	KM	Advisors meeting with J. DelConte, A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.70
05/26/20	KM	Meeting with D. Fogel (Purdue) and K. McCafferty, R. Sublett (both AlixPartners) re: org structure for BIG 4 meeting 5/27.	1.40
05/26/20	KM	Analysis and slide creation re: Rhodes Quality re-org and re-engineering.	1.80
05/26/20	JD	Call with J. DelConte, K. McCafferty, R. Sublett (all AlixPartners), D. Lundie, J. Doyle, R. Shambren, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. Turner, R. Schnitzler (both PJT), M. Florence, M. Gibson, J. Bragg (all Skadden), C. Robertson (Davis Polk) re: Project Catalyst	2.00
05/26/20	JD	Advisors meeting with J. DelConte, A. DePalma, K. McCafferty, R. Sublett (all AlixPartners) re: Project Catalyst.	0.70
05/26/20	JD	Call with R. Aleali (Purdue) re: upcoming board meeting.	0.60
05/26/20	JD	Review and provide comments on Project Catalyst timeline and VDR index.	0.80
05/26/20	JD	Correspondence with S. Lemack (AlixPartners) re: critical vendor payments.	0.30
05/26/20	JD	Correspondence with R. Sublett (AlixPartners) and R. Schnitzler (PJT) re: Project Catalyst.	0.40
05/26/20	JD	Review opioid only and near term sale scenario forecast headcount reduction assumptions.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/26/20	JD	Call with R. Sublett, J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: PMO and data room index for Project Catalyst.	0.60
05/26/20	JD	Review final board slides re: potential BD deal.	0.30
05/26/20	JD	Review draft Board slides re: April financial performance.	1.00
05/26/20	NAS	Review new Mundipharma diligence materials provided by Huron.	1.00
05/26/20	GJK	Analysis for Mundipharma interim diligence re: review of Huron provided information and follow up email exchange with Huron	1.60
05/26/20	GJK	Analysis of potential downside drivers for Mundipharma beyond noted risk adjustments	2.00
05/26/20	GJK	Review Mundipharma diligence responses.	0.30
05/26/20	IA	Drafted LTRP analysis showing 2020, 2021 and 2022 estimated payments with various reduction assumptions as well as splits by grant year.	3.60
05/26/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: open critical vendor updates and executed trade agreements	0.40
05/26/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: open critical vendor updates and executed trade agreements	0.40
05/27/20	SKL	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: the latest status request regarding critical vendor trade agreements.	0.40
05/27/20	MH	Meeting with M. Hartley, S. Lemack (both AlixPartners) re: the latest status request regarding critical vendor trade agreements.	0.40
05/27/20	LJD	Prepare for and attend board meeting	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/27/20	GJK	Review of N. Simon (AlixPartners) comparison of COGS between Mundipharma YEE and Revised Forecast	0.50
05/27/20	GJK	Asses potential COGS improvement drivers between Mundipharma YEE budget and revised forecast (including review of Tech Ops and previous comparison of top ten by country products)	2.30
05/27/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC update.	0.20
05/27/20	NAS	Review new materials provided by Huron/Mundipharma and compare to prior sources.	2.00
05/27/20	JD	Review correspondence with Willis Towers Watson re: compensation analysis.	0.40
05/27/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC update.	0.20
05/27/20	JD	Review historical financial analysis reports posted to the VDR and correspondence with M. Atkinson (Province) re: same.	1.00
05/27/20	JD	Review draft summary compensation analysis prepared by I. Arana (AlixPartners) for Willis Towers Watson.	0.70
05/27/20	JD	Call with C. Robertson (Davis Polk) re: open items and board meeting prep.	0.40
05/27/20	JD	Participate in PPI Board meeting.	2.80
05/27/20	JD	Call with D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. DelConte (partial attendance), K. McCafferty, R. Sublett, (AlixPartners), PJT, Skadden re: Project Catalyst	1.70
05/27/20	JD	Review and provide comments on updated Project Catalyst timeline.	0.20
05/27/20	JD	Review fee examiner retention docs and prepare cost	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		forecast and correspondence with R. Brown (Purdue) re: same.	
05/27/20	JD	Prepare response to UCC diligence questions re: business forecast sensitivity analysis.	0.90
05/27/20	KM	Edit deck re: org structure for BIG 4 meeting 5/27	0.60
05/27/20	KM	Meeting with D. Lundie, D. Fogel, V. Mancinelli, R. Shamblen, D. McGuire, J. Northington (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes restructuring recommendations	2.30
05/27/20	KM	Meeting follow up email to D. Lundie (Purdue) re: Rhodes restructuring recommendations	0.20
05/27/20	KM	Call with D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (AlixPartners), PJT, Skadden re: Project Catalyst	1.90
05/27/20	KM	Analysis and process development re. R&D restructuring support processes and KPIs.	0.40
05/27/20	KM	Restructuring analysis re: Rhodes Pharma	1.00
05/27/20	KM	Analysis re. Rhodes restructuring reconciliation to Jan Board count for presentation.	0.30
05/27/20	KM	Create report and slides re. Rhodes restructuring summary for presentation to management.	0.70
05/27/20	KM	Call with D. Fogel, D. Lundie, (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: org charts and severance plans ahead of the Big Four management meeting	1.60
05/27/20	ADD	Discussion with R. Sublett (AlixPartners) re: Project Catalyst VDR	0.30
05/27/20	RDS	Provide commentary to back up R&D rationalization methodology based on management discussions.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/27/20	RDS	Refine executive summary section for meeting with D. Lundie (Purdue).	1.20
05/27/20	RDS	Call with D. Fogel, D. Lundie, (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: org charts and severance plans ahead of the Big Four management meeting	1.60
05/27/20	RDS	Meeting with D. Lundie, D. Fogel, V. Mancinelli, R. Shamblen, D. McGuire, J. Northington (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes restructuring recommendations	2.30
05/27/20	RDS	Call with D. Lundie, J. Doyle, R. Shamblen, D. Fogel, R. Aleali, J. Lowne, P. Strassburger (all Purdue), J. DelConte, K. McCafferty, R. Sublett, (AlixPartners), PJT, Skadden re: Project Catalyst	1.90
05/27/20	RDS	Call with C. Robertson (DPW) re: VDR for Project Catalyst	0.20
05/27/20	RDS	Discussion with A. DePalma (AlixPartners) re: Project Catalyst VDR	0.30
05/28/20	RDS	Call with D. Fogel, V. Mancinelli, R. Shamblen, J. Northington, D. McGuire, J. Doyle (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: update on transformation efforts.	2.40
05/28/20	RDS	Correspondence with Rhodes team re: Project Catalyst diligence requests and review of VDR data request list re: the same	0.60
05/28/20	RDS	Review business plan targets as provided and prepare analysis to share with big four re: targets.	1.40
05/28/20	RDS	Research and correspondence with D. Fogel (Purdue) re: Project Catalyst scorecard.	0.80
05/28/20	RDS	Review and assemble working group list for Project Catalyst and correspondence with PJT and DPW RE the same	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/28/20	RDS	Review VDR contents in preparation for meeting with Project Catalyst meeting	1.70
05/28/20	RDS	Call with A. DePalma, K. McCafferty, R. Sublett (all AlixPartners), D. Fogel, R. Shamblen (both Purdue), R. Schnitzler (PJT) re. Project Catalyst VDR Index	0.90
05/28/20	ADD	Call with A. DePalma, K. McCafferty, R. Sublett (all AlixPartners), D. Fogel, R. Shamblen (both Purdue), R. Schnitzler (PJT) re. Project Catalyst VDR Index	0.90
05/28/20	KM	Analysis and reporting re. Rhodes organization restructuring for presentation at Senior Leadership meeting.	2.20
05/28/20	KM	Analysis and strawman for Rhodes BD process re-engineering	1.40
05/28/20	KM	Analysis and strawman for Rhodes finance re-engineering	1.10
05/28/20	KM	Develop process re. project Catalyst VDR and document tracking development.	0.50
05/28/20	KM	Call with A. DePalma, K. McCafferty, R. Sublett (all AlixPartners), D. Fogel, R. Shamblen (both Purdue), R. Schnitzler (PJT) re. Project Catalyst VDR Index	0.90
05/28/20	KM	Call with D. Fogel, V. Mancinelli, R. Shamblen, J. Northington, D. McGuire, J. Doyle (all Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: update on transformation efforts.	2.40
05/28/20	KM	Support restructuring and communication re. Rhodes organization restructuring to leadership team.	0.40
05/28/20	JD	Review correspondence from R. Sublett (AlixPartners) and D. Fogel (Purdue) re: Project Catalyst scorecard.	0.50
05/28/20	JD	Correspondence with PJT re: sensitivity forecast assumptions.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/28/20	JD	Review correspondence and draft responses from management re: D&P business plan diligence questions.	0.60
05/28/20	JD	Review VDR proposals re: Project Catalyst.	0.40
05/28/20	JD	Call with Davis Polk (M. Huebner, E. Vonnegut), PJT (J. O'Connell, R. Schnitzler, J. Turner), Purdue (M. Kesselman, R. Aleali), Dechert (S. Birnbaum, D. Gentin Stock) and AlixPartners (J. DelConte, S. Lemack) re: Monday side by side prep call.	0.60
05/28/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst and board meeting follow ups.	1.00
05/28/20	JD	Participate in PPI Board meeting.	3.30
05/28/20	JD	Participate in afternoon PPI board meeting.	1.00
05/28/20	NAS	Respond to trade agreement question from Purdue/Rhodes Vendor Management Team.	0.50
05/28/20	NAS	Analyze potential upside scenarios for Mundipharma business plan.	1.90
05/28/20	GJK	Review of free cash flow items for potential back up support for Capex and NWC.	2.00
05/28/20	GJK	Assessment of potential upside opportunities for Mundipharma including cost structure improvements from TechOps and upside revenue	2.00
05/28/20	IA	Update LTRP analysis to include additional scenarios requested by Willis Towers Watson.	2.80
05/28/20	LJD	Prepare for and attend board meeting	3.80
05/28/20	SKL	Prepare for and participate in call with Davis Polk (M. Huebner, E. Vonnegut), PJT (J. O'Connell, R. Schnitzler, J. Turner), Purdue (M. Kesselman, R. Aleali), Dechert (S. Birnbaum, D. Gentin Stock) and AlixPartners (J. DelConte, S. Lemack) re: Monday side by side prep call.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/29/20	IA	Update LTRP analysis to include changes requested by Willis Towers Watson	1.30
05/29/20	GJK	Call with I. McClatchey (Norton Rose) re: diligence process.	0.80
05/29/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: potential EBIT upsides to Mundipharma business plan; diligence updates	0.80
05/29/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) re: Australia TGA revised indications and impact on market	0.20
05/29/20	GJK	Review of current draft of Mundi interim diligence report and planning for incorporation of valuation; identification of additional back up detail to note.	1.30
05/29/20	GJK	Follow up discussion with G. Koch, N. Simon (both AlixPartners) re: questions and responses from advisors and Huron regarding outstanding diligence items	0.30
05/29/20	GJK	Call with G. Koch and J. DeLConte (both AlixPartners) re: IAC catch up.	0.20
05/29/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: potential EBIT upsides to Mundipharma business plan; diligence updates	0.80
05/29/20	NAS	Research new pharmaceutical regulations in Australia for Mundipharma diligence.	1.70
05/29/20	NAS	Correspondence with other diligence advisors re: Mundipharma diligence requests.	0.40
05/29/20	NAS	Follow up discussion with G. Koch, N. Simon (both AlixPartners) re: questions and responses from advisors and Huron regarding outstanding diligence items	0.30
05/29/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) re: Australia TGA revised indications and impact on market.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/29/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC catch up.	0.20
05/29/20	JD	Review and provide comments on Rhodes Tech vendor spend analysis.	0.40
05/29/20	JD	Review updated compensation analysis from I. Arana (AlixPartners).	0.30
05/29/20	JD	Catch up call with R. Sublett and J. DelConte (both AlixPartners) re: Project Catalyst.	0.30
05/29/20	JD	Review updated analysis from I. Arana (AlixPartners) re: compensation review.	0.70
05/29/20	JD	Review Rhodes Tech contract list and correspondence with A. DePalma (AlixPartners) and J. Doyle (Purdue) re: same.	0.60
05/29/20	JD	Review and provide comments on updated side by side analysis from PJT.	0.60
05/29/20	JD	Review and provide comments on Project Catalyst working group list.	0.20
05/29/20	JD	Review correspondence from C. Oluwole (Davis Polk) and R. Aleali (Purdue) re: board minute productions.	0.30
05/29/20	KM	Analysis and document editing re: alternate supply chain options for RALP	1.30
05/29/20	KM	Analysis and document editing re: RT org structure	0.70
05/29/20	KM	Analysis and edits re: supply chain organization	0.50
05/29/20	KM	Call with J. Northington (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: review of Wilson and SC org structure	0.70
05/29/20	KM	Analysis re: org structure reconciliation vs Jan Budget and short term targets	0.90
05/29/20	KM	Call with D. Fogel, (Purdue), K. McCafferty, R. Sublett	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		(both AlixPartners) re: Rhodes restructuring adjustments from leadership team	
05/29/20	KM	Analysis and document editing re: RP org structure changes	0.50
05/29/20	KM	Develop scenario re: RP org structure changes	0.50
05/29/20	KM	Create and edit slide re: org structure options.	0.30
05/29/20	KM	Call with R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: latest iteration of strategic initiatives.	0.60
05/29/20	KM	Create slide re: RP org structure options.	0.10
05/29/20	KM	Call with D. McGuire (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: latest iteration of strategic initiatives.	0.50
05/29/20	RDS	Catch up call with R. Sublett and J. DelConte (both AlixPartners) re: Project Catalyst.	0.30
05/29/20	RDS	Call with R. Shamblen (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: latest iteration of strategic initiatives.	0.60
05/29/20	RDS	Call with D. McGuire (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: latest iteration of strategic initiatives.	0.50
05/29/20	RDS	Review of VDR requests	1.10
05/29/20	RDS	Call with J. Northington (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: review of Wilson and SC org structure	0.70
05/29/20	RDS	Prepare presentation org structure for Rhodes pharma R&D functions and share with D. Lundie (Purdue).	0.70
05/29/20	RDS	Correspondence with Project Catalyst team re: case updates and distribution lists / WGL	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
05/29/20	RDS	Review vendor data for Project Catalyst	0.50
05/29/20	RDS	Process updates to org structure from Big 4 RALP management meeting	2.40
05/29/20	RDS	Call with D. Fogel, (Purdue), K. McCafferty, R. Sublett (both AlixPartners) re: Rhodes restructuring adjustments from leadership team	1.20
05/29/20	RDS	Review Project Catalyst board communication materials	0.30
05/30/20	RDS	Correspondence with D. Lundie (Purdue) re: headcount reduction recommendations.	1.30
05/30/20	RDS	Assemble aggregated VDR request list	0.60
05/30/20	RDS	Review headcount reduction commentary from Rhodes management meeting materials	1.00
05/30/20	RDS	Review revised draft of APA and TSA	1.60
05/30/20	KM	Edit slide and response for D. Lundie (Purdue).	0.70
05/31/20	JD	Review updated draft side by side analyses.	0.80
05/31/20	JD	Review previous Board materials for summary information.	0.50
Total			705.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	4.40	515.00	2,266.00
Sam K Lemack	1.60	515.00	824.00
Nate A Simon	110.10	515.00	56,701.50
Isabel Arana de Uriarte	40.10	690.00	27,669.00
Ryan D Sublett	107.90	735.00	79,306.50
Gabe J Koch	185.20	840.00	155,568.00
Michael Hartley	1.40	840.00	1,176.00
Jesse DelConte	91.30	950.00	86,735.00
Kevin M McCafferty	142.30	950.00	135,185.00
Lisa Donahue	21.30	1,195.00	25,453.50
Total Hours & Fees	705.60		570,884.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Executory Contracts
Client/Matter # 012589.00108

Date	Consultant	Description of Services	Hours
05/08/20	JD	Correspondence with R. Aleali (Purdue) re: unpaid cure amounts.	0.30
05/12/20	JD	Review payment status of Avrio lease and open cure amounts.	0.20
Total			0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Executory Contracts
Client/Matter # 012589.00108

Fee Recap:

Consultant	Hours	Rate	Amount
Jesse DelConte	0.50	950.00	475.00
Total Hours & Fees	0.50		475.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
05/08/20	KG	Create tenth production for delivery.	1.80
		Total	<u>1.80</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Kristina Galbraith	1.80	645.00	1,161.00
Total Hours & Fees	1.80		1,161.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Date	Consultant	Description of Services	Hours
05/08/20	LJD	Call with internal AlixPartners team re: Purdue disclosure requirements.	0.40
05/18/20	KAS	Review and circulate updated parties-in-interest.	0.30
05/18/20	ESK	Email internal re: obtaining updated PII list.	0.20
05/18/20	JD	Review updated parties-in-interest list to provide to AlixPartners legal.	0.40
05/18/20	BFF	Follow up with J. DeConte (AlixPartners) re: updated parties-in-interest list	0.10
05/26/20	KAS	Review and Circulate updated parties-in-interest list.	0.20
Total			1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Retention and Engagement Administration
Client/Matter # 012589.00112

Fee Recap:

Consultant	Hours	Rate	Amount
Brooke F Filler	0.10	445.00	44.50
Kaitlyn A Sundt	0.50	510.00	255.00
Elizabeth S Kardos	0.20	710.00	142.00
Jesse DelConte	0.40	950.00	380.00
Lisa Donahue	0.40	1,195.00	478.00
Total Hours & Fees	1.60		1,299.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
05/01/20	TB	Prepare March 2020 monthly fee statement.	0.50
05/01/20	TB	Update fee and expense status chart.	0.20
05/01/20	JD	Review and provide comments re: draft fee statement for March 2020.	3.30
05/04/20	JD	Final review of March 2020 monthly fee application.	0.50
05/05/20	TB	Prepared 7th Monthly Fee Statement and exhibits for March 2020.	1.70
05/05/20	KAS	Review draft for 7th Monthly Fee Statement from T. Brewer (AlixPartners).	0.60
05/07/20	LJD	Review and comment on fee statement.	0.90
05/14/20	IA	Review professional fees for April 2020 monthly fee statement.	1.20
05/14/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	4.00
05/14/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	3.30
05/14/20	MSM	Further preparation of professional fees for April 2020 monthly fee statement.	2.70
05/15/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	3.00
05/15/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	2.60
05/16/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	3.50
05/16/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	2.60
05/16/20	MSM	Further preparation of professional fees for April 2020 monthly fee statement.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
05/17/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	3.50
05/17/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	3.90
05/17/20	TB	Prepare professional fees for April 2020 monthly fee statement.	1.60
05/19/20	TB	Prepare professional fees for April 2020 monthly fee statement.	0.80
05/19/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	1.90
05/20/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	3.20
05/20/20	MSM	Continue to prepare professional fees for April 2020 monthly fee statement.	2.00
05/20/20	IA	Review professional fees for April 2020 monthly fee statement.	1.60
05/21/20	TB	Prepare professional fees for April 2020 monthly fee statement.	1.30
05/21/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	2.00
05/22/20	IA	Review professional fees for April 2020 monthly fee statement.	1.00
05/26/20	IA	Review professional fees for April 2020 monthly fee statement.	2.00
05/27/20	JD	Initial review of fee statement.	0.50
05/27/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	1.80
05/29/20	MSM	Prepare professional fees for April 2020 monthly fee statement.	2.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
			Total
			<u>63.40</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Melanie McCabe	45.70	415.00	18,965.50
Tammy Brewer	6.10	450.00	2,745.00
Kaitlyn A Sundt	0.60	510.00	306.00
Isabel Arana de Uriarte	5.80	690.00	4,002.00
Jesse DelConte	4.30	950.00	4,085.00
Lisa Donahue	0.90	1,195.00	1,075.50
Total Hours & Fees	63.40		31,179.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
05/01/20	JD	Participate telephonically in court hearing re: discovery.	2.70
05/01/20	RC	Call in to portion of the court hearing re: discovery issues raised by the UCC and Nonconsenting States against the Sacklers and IACs.	2.00
05/01/20	NAS	Partial attendance (telephonically) Purdue Pharma discovery hearing.	0.50
Total			5.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Nate A Simon	0.50	515.00	257.50
Jesse DelConte	2.70	950.00	2,565.00
Richard Collura	2.00	1,090.00	2,180.00
Total Hours & Fees	5.20		5,002.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/01/20	SJC	Analysis of 2018 royalties for report 1B.	3.00
05/01/20	SJC	Analysis of 2017 royalties for report 1B.	2.50
05/01/20	SJC	Continue analysis of 2017 royalties for report 1B.	2.00
05/01/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: shared services charges between Purdue and Rhodes.	0.20
05/01/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: shared services charges between Purdue and Rhodes.	0.20
05/01/20	FOS	Review documents and SAP data re: shared services charges between Purdue and Rhodes.	2.60
05/01/20	MFR	Review and analysis of shares service charges between Purdue and Rhodes.	3.20
05/01/20	FOS	Continue to review documents and SAP data re: shared services charges between Purdue and Rhodes.	2.50
05/01/20	RC	Review and provide comments on supporting documentation gathered in response to the UCC's requests re: Ex-US distributions.	1.10
05/01/20	JDH	Continue to prepare 2010 Distribution documentation.	3.40
05/01/20	KS	Compile the royalty payments for 2015.	2.60
05/01/20	KS	Continue to compile the royalty payments for 2015.	1.20
05/01/20	KS	Compile the royalty payments for 2016.	2.30
05/01/20	KS	Continue to compile the royalty payments for 2016.	1.90
05/01/20	JDH	Prepare 2010 Distribution documentation.	3.50
05/01/20	RC	Continue to review documentation related to the UCC's initial Ex-US distribution selections and provide comments.	2.30
05/04/20	RC	Continue to review and comment on support documentation re: the UCC's initial selection of Ex-US distributions.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/04/20	RC	Review and comment on documentation gathered in response to the UCC's additional Ex-US distribution selections.	1.70
05/04/20	RC	Review additional information gathered in response to the UCC's requests related to tax distributions.	0.70
05/04/20	JDH	Prepare 2010 Tax distribution documentation	3.20
05/04/20	JDH	Continue preparation of 2010 Tax distribution documentation.	2.50
05/04/20	KS	Compile the royalty payments data for 2016.	1.80
05/04/20	JDH	Further preparation of 2010 Tax distribution documentation	2.20
05/04/20	RC	Review documentation gathered in response to requests from the UCC re: Ex-US distributions.	1.90
05/04/20	RC	Review documentation gathered in response to requests from the UCC re: Tax distributions.	1.60
05/04/20	MFR	Review and analysis of accounts payables related to the intercompany and non-cash transfers report.	2.90
05/04/20	MFR	Review and analysis of royalty payments related to the intercompany and non-cash transfers report and supporting analyses.	1.80
05/04/20	MFR	Review of and revisions to the intercompany and non-cash transfers report.	2.10
05/04/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.10
05/04/20	FOS	Review documents and SAP data re: shared services charges between Purdue and Rhodes.	3.50
05/04/20	FOS	Analyze data and documentation re: royalties between Purdue and IACs.	1.00
05/04/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft	0.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		intercompany and non-cash transfers report.	
05/04/20	SJC	Continue review of additional bank statements received supporting 2011-2014 distributions.	1.00
05/04/20	SJC	Review and respond to comments and questions re: distribution analysis previously performed.	2.50
05/04/20	SJC	Review of additional bank statements received supporting 2015 distributions.	1.80
05/04/20	SJC	Review of additional bank statements received supporting 2011 distributions.	1.50
05/04/20	SJC	Review of additional bank statements received supporting 2013 distributions.	1.50
05/05/20	SJC	Review of additional bank statements received supporting 2013 distributions.	3.00
05/05/20	SJC	Continue review of additional bank statements received supporting 2013 distributions.	1.00
05/05/20	SJC	Review of additional bank statements received supporting 2011 distributions.	2.50
05/05/20	SJC	Continue review of additional bank statements received supporting 2013 distributions.	1.50
05/05/20	MFR	Conference call with J. Lowne, J. Carlisle, E. Liesman, W. DiNicola, E. Nowakowski, T. Au, D. Wooten (all Purdue) M. Rule, F. Silva (both AlixPartners) re: pending items on draft intercompany and non-cash transfers report.	0.60
05/05/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
05/05/20	FOS	Conference call with J. Lowne, J. Carlisle, E. Liesman, W. DiNicola, E. Nowakowski, T. Au, D. Wooten (all Purdue) M. Rule, F. Silva (both AlixPartners) re: pending items on draft intercompany and non-cash transfers report.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/05/20	MFR	Review of accounts payable data related to the intercompany and non-cash transfers report and supporting analyses.	2.40
05/05/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	3.10
05/05/20	FOS	Continue to analyze and reconcile data re: shared services charges between Purdue and Rhodes entities.	2.40
05/05/20	FOS	Compose email to J. Lowne (Purdue) re: shared services charges between PPLP and Rhodes entities.	0.10
05/05/20	FOS	Compose email to W. DiNicola (Purdue) re: Intercompany account settlement files for Rhodes Tech and Rhodes Pharma.	0.10
05/05/20	FOS	Compose email to E. Liesman (Purdue) re: shared services charges between Rhodes and PPLP.	0.10
05/05/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
05/05/20	FOS	Analyze and reconcile data re: shared services charges between Purdue and Rhodes entities.	2.50
05/05/20	JDH	Continue preparation of 2010 Tax distribution documentation.	2.20
05/05/20	JDH	Prepare 2010 Tax distribution documentation	2.60
05/05/20	JDH	Prepare 2010 Non-tax distributions documentation.	3.60
05/05/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: the UCC's Schedule A diligence requests and status of responses.	0.70
05/05/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: the UCC's Schedule A diligence requests and responses thereto.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/05/20	RC	Follow-up call with R. Collura, A. DePalma (both AlixPartners) re: responding to Davis Polk's questions related the UCC's Schedule A diligence requests.	0.20
05/05/20	RC	Review Schedule A diligence requests and provide comments to status update for Davis Polk.	0.60
05/05/20	RC	Review and comment on supporting documentation gathered in response to the UCC's Ex-Us distributions.	1.60
05/05/20	RC	Continue review of supporting documentation gathered in response to the UCC's Ex-Us distributions.	1.40
05/05/20	RC	Review documentation related UCC's request for documentation related to loans.	1.10
05/05/20	RC	Review documentation gathered as support to the cash transfers of value report and in response to various parties requests.	0.80
05/05/20	ADD	Follow-up call with R. Collura, A. DePalma (both AlixPartners) re: responding to Davis Polk's questions related the UCC's Schedule A diligence requests.	0.20
05/05/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: the UCC's Schedule A diligence requests and status of responses.	0.70
05/05/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: the UCC's Schedule A diligence requests and responses thereto.	0.20
05/06/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: the intercompany and non-cash transfers of value report.	0.60
05/06/20	RC	Conference call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/06/20	RC	Review information related to the intercompany and non-cash transfers of value report.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/06/20	RC	Review and provide comments re: additional work to perform in connection with gathering support for Ex-US and tax distributions.	1.40
05/06/20	RC	Review supporting documentation gathered in response to the UCC's requests for additional distribution selections.	1.20
05/06/20	RC	Review additional information related to the intercompany and non-cash transfers of value report.	0.70
05/06/20	JDH	Review 2012 Distribution	3.00
05/06/20	JDH	Continue to review 2012 Distribution.	2.20
05/06/20	FOS	Compose email to J. Lowne (Purdue) re: draft intercompany and non-cash transfers report pending items.	0.10
05/06/20	FOS	Conference call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/06/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.00
05/06/20	FOS	Calls with F. Silva, M. Rule (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
05/06/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.00
05/06/20	MFR	Review of accounts payable data related to the intercompany and non-cash transfers report.	2.30
05/06/20	MFR	Review and analysis of royalty payments related to the intercompany and non-cash transfers report and supporting analyses	2.60
05/06/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/06/20	MFR	Conference call with M. Clarens, E. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/06/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
05/06/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: the intercompany and non-cash transfers of value report.	0.60
05/06/20	SJC	Review and respond to comments and questions re: distribution analysis previously performed.	2.00
05/06/20	SJC	Review of additional bank statements received to identify those that supported distribution samples selected by Province.	3.00
05/06/20	SJC	Continue review of additional bank statements received to identify those that supported distribution samples selected by Province.	3.00
05/07/20	SJC	Compilation of support from SAP for 2013 distributions as well as analysis of journal entries.	3.00
05/07/20	SJC	Continue compilation of support from SAP for 2013 distributions as well as analysis of journal entries.	2.00
05/07/20	SJC	Compilation of support from SAP for 2011 distributions as well as analysis of journal entries.	3.00
05/07/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.40
05/07/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.40
05/07/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.80
05/07/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: status of intercompany and non-cash transfers of value report	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/07/20	MFR	and next steps.	
05/07/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.10
05/07/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/07/20	FOS	Edit draft report re: intercompany and non-cash transfers.	2.50
05/07/20	FOS	Compose email to W. DiNicola (Purdue) re: Shared services charges between Purdue and Rhodes entities.	0.20
05/07/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.80
05/07/20	FOS	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/07/20	JDH	Continue to prepare 2010 Distribution documentation.	2.60
05/07/20	JDH	Prepare 2010 Distribution documentation.	3.00
05/07/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: status of intercompany and non-cash transfers of value report and next steps.	0.60
05/07/20	RC	Review comments from J. Lowne (Purdue) related to the intercompany and non-cash transfers of value report.	0.50
05/07/20	RC	Review status of diligence requests made to TXP Services.	0.40
05/07/20	RC	Review Schedule A diligence list and update TXP diligence tracker.	0.30
05/07/20	RC	Review additional documentation gathered in response to the UCC's requests related to royalties.	0.80
05/07/20	RC	Review additional documentation gathered in response to the UCC's requests related to transactions with IACs.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/07/20	RC	Review updated support documentation compiled in response to the UCC's requests re: the cash transfers of value report.	1.60
05/07/20	JD	Review draft investigation report 1B and commentary from J. Lowne (Purdue).	3.30
05/08/20	JD	Review correspondence and open questions from management re: investigation report 1B.	0.50
05/08/20	RC	Review and comment on responses to additional testing selections by the UCC's advisors.	1.60
05/08/20	RC	Review comments received in connection with the intercompany and non-cash transfers of value report.	0.40
05/08/20	RC	Review status of responses to the UCC's request for support documentation.	0.70
05/08/20	RC	Review royalty information gathered in response to the UCC's requests.	0.50
05/08/20	RC	Review support documentation gathered in response to requests for IAC agreements.	0.70
05/08/20	RC	Call with R. Collura, J. DelConte (both AlixPartners) re: status of the intercompany and non-cash transfers report and special committee related work.	0.30
05/08/20	JDH	Prepare 2010 non-tax distributions documentation.	2.80
05/08/20	JDH	Review of 2010 tax distributions.	2.20
05/08/20	JDH	Continue to prepare 2010 non-tax distributions documentation.	2.50
05/08/20	FOS	Conference call with M. Clarens (Davis Polk), E. Kim (Davis Polk), A. Whisenant (Davis Polk), M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/08/20	FOS	Conference call with M. Rule, F. Silva (both AlixPartners)	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		re: reconciliation of shared services charges between Purdue and Rhodes entities.	
05/08/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.30
05/08/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.00
05/08/20	MFR	Conference call with M. Clarens (Davis Polk), E. Kim (Davis Polk), A. Whisenant (Davis Polk), M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/08/20	MFR	Conference call with M. Rule, F. Silva (both AlixPartners) re: reconciliation of shared services charges between Purdue and Rhodes entities.	0.60
05/08/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.40
05/08/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.20
05/08/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	0.80
05/08/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.30
05/08/20	SJC	Continue compilation of support from SAP for 2011 distributions as well as analysis of journal entries.	3.00
05/08/20	SJC	Compilation of supporting documents from SAP for 2009 distributions.	2.00
05/09/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.50
05/10/20	FOS	Analyze and reconcile SAP data re: shared services	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		charges between Purdue and Rhodes entities.	
05/11/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.60
05/11/20	FOS	Email to R. Ellis Ochoa (AlixPartners) re: Infinity Pharmaceuticals non-cash transfer.	0.10
05/11/20	FOS	Compose email to J. Lowne (Purdue) re: pending items on draft intercompany and non-cash transfers report.	0.30
05/11/20	FOS	Review documents and edit draft report re: intercompany and non-cash transfers report.	2.00
05/11/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.50
05/11/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.50
05/11/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	1.70
05/11/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.30
05/11/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.60
05/11/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.20
05/11/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.60
05/11/20	SJC	Continue compilation of supporting documents from SAP for 2009 distributions from SAP and related analysis.	3.00
05/11/20	SJC	Further compilation of supporting documents from SAP for 2009 distributions from SAP and related analysis.	1.30
05/11/20	SJC	Compilation of supporting documents from SAP for 2009	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		distributions from SAP and related analysis.	
05/11/20	REO	Review intercompany transactions re: non-cash transfers to PRA.	0.60
05/11/20	JDH	Continue to prepare 2010 Tax distribution documentation.	2.30
05/11/20	JDH	Prepare 2010 Tax distribution documentation	2.50
05/11/20	JDH	Perform 2010 QC review.	2.80
05/11/20	RC	Review comments related to the intercompany and non-cash transfers of value report.	0.50
05/11/20	RC	Review documentation gathered in connection with tax distributions.	1.60
05/11/20	RC	Review documentation gathered in connection with US distributions.	1.40
05/11/20	RC	Review information re: tax information related requests.	1.10
05/11/20	RC	Review information related to transactions with the IACs.	0.80
05/11/20	RC	Review documentation related to non-cash distributions.	1.30
05/11/20	JD	Review correspondence between J. Lowne (Purdue) and F. Silva (AlixPartners) re: Report 1B open items. Review open diligence items and back up information.	1.00
05/12/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: the intercompany and non-cash transfers of value report.	0.70
05/12/20	RC	Review and respond to questions from Province.	0.20
05/12/20	RC	Review schedules prepared in connections with the intercompany and non-cash transfers of value report.	1.10
05/12/20	RC	Review and comment on documentation supporting the tax distributions.	1.40
05/12/20	RC	Review and comment on documentation supporting the Ex-US loans.	1.10
05/12/20	RC	Review and analysis of tax related information gathered	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		in response to requests from the UCC.	
05/12/20	RC	Review documentation related rent and real estate taxes.	0.60
05/12/20	RC	Review additional diligence requests related to license agreements with IACs.	0.10
05/12/20	RC	Review additional documents provided by TXP's counsel and communicate with Davis Polk.	0.50
05/12/20	JDH	Begin to finalize 2010 Distribution documentation.	3.00
05/12/20	JDH	Set up 2008 Distribution documentation.	1.80
05/12/20	JDH	Prepare 2008 Tax distribution documentation.	1.00
05/12/20	JDH	Continue to finalize 2010 Distribution documentation.	1.90
05/12/20	SJC	Compile and evaluate 2009 distribution support from SAP.	3.00
05/12/20	SJC	Review of 2009 distribution support and analysis.	3.00
05/12/20	SJC	Continue review of 2009 distribution support and analysis.	2.00
05/12/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.30
05/12/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	1.80
05/12/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.00
05/12/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: the intercompany and non-cash transfers of value report.	0.70
05/12/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.40
05/12/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.20
05/12/20	FOS	Continue to analyze and reconcile SAP data re: shared	3.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/12/20	FOS	services charges between Purdue and Rhodes entities.	
05/12/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.30
05/12/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.40
05/13/20	FOS	Call with J. Lowne (Purdue) re: Purdue Canada reimbursement of expenses.	0.10
05/13/20	FOS	Conference call with J. Lowne (Purdue), M. Rule, F. Silva (both AlixPartners) re: status of pending requests on draft intercompany and non-cash transfers report.	0.40
05/13/20	FOS	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.70
05/13/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	1.50
05/13/20	FOS	Compose email to R. Collura, S. Canniff, K. Shibuya, J. Hecht, and M. Rule (all AlixPartners) re: quality control and review of draft intercompany and non-cash transfers report.	0.30
05/13/20	FOS	Compose emails to J. Lowne (Purdue) re: draft intercompany and non-cash transfers report.	0.20
05/13/20	FOS	Compose and edit draft report re: intercompany and non-cash transfers.	2.40
05/13/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.30
05/13/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.50
05/13/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.10
05/13/20	MFR	Review and analysis of intercompany accounts related to	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		the intercompany and non-cash transfers report and supporting analyses.	
05/13/20	MFR	Conference call with J. Lowne (Purdue), M. Rule, F. Silva (both AlixPartners) re: status of pending requests on draft intercompany and non-cash transfers report.	0.40
05/13/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.70
05/13/20	MFR	Review of email from F. Silva (AlixPartners) re: quality control and review of draft intercompany and non-cash transfers report.	0.20
05/13/20	FOS	Continue to compose and edit draft report re: intercompany and non-cash transfers.	2.40
05/13/20	SJC	Review and summary of documents received from Haug Partners on 5.12.20 and updating bank statement index for new documents received.	3.00
05/13/20	SJC	Continue review and summary of documents received from Haug Partners on 5.12.20 and updating bank statement index for new documents received.	3.00
05/13/20	SJC	Continue review and summary of documents received from Haug Partners on 5.12.20 and updating bank statement index for new documents received.	0.90
05/13/20	SJC	Review of SAP documents for 2009 distributions.	1.10
05/13/20	JDH	Continue to prepare 2008 Distribution documentation.	2.00
05/13/20	JDH	Prepare 2008 Distribution documentation.	3.10
05/13/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to diligence requests.	0.80
05/13/20	RC	Review and respond to Davis Polk re: email from TXP's outside counsel.	0.40
05/13/20	RC	Review documents provided by TXP in response to	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		diligence requests and communicate with Davis Polk re: same.	
05/13/20	RC	Review information provided by TXP's outside in response to diligence requests.	0.60
05/13/20	RC	Review documentation related to transactions with IACs.	1.30
05/13/20	RC	Communicate with Davis Polk re: available bank statement information.	0.20
05/13/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to diligence requests.	0.80
05/13/20	ADD	Review material provided by the client in response to diligence requests for completeness and consistency.	0.70
05/14/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: additional updates to the TXP diligence tracker.	0.40
05/14/20	RC	Call with R. Collura, M. Rule (both AlixPartners) re: status of the intercompany and non-cash transfers of value report.	0.30
05/14/20	RC	Review status of diligence requests from the UCC.	0.70
05/14/20	RC	Review and update TXP diligence tracker based on additional documentation received.	0.30
05/14/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: additional updates to the TXP diligence tracker.	0.40
05/14/20	RC	Review and respond to questions from Davis Polk re: bank statement information.	0.10
05/14/20	JDH	Review Report 1B	3.60
05/14/20	JDH	Call with E. Liesman (PPLP) re: Report 1B.	0.60
05/14/20	JDH	Perform 2008 Distribution testing.	1.20
05/14/20	JDH	Calls with J. Hecht, F. Silva (both AlixPartners) re: charges between Purdue and TXP for services.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/14/20	JDH	Conference call with E. Liesman (Purdue), J. Hecht, F. Silva (both AlixPartners) re: charges between Purdue and TXP for services.	0.60
05/14/20	KS	Review the transactions in SAP between the IAC and PPLP.	3.00
05/14/20	SJC	Review of report 3B - reviewed data retrieved from SAP, checked report to PBCs, reviewed for accuracy, reconciled amounts contained within report and PBCs.	2.20
05/14/20	SJC	Analysis of OSR rent related payments in SAP.	3.00
05/14/20	SJC	Analysis of intercompany transfer related payments in SAP for sale of goods.	1.00
05/14/20	SJC	Continue review of report 3B - reviewed data retrieved from SAP, checked report to PBCs, reviewed for accuracy, reconciled amounts contained within report and PBCs.	2.00
05/14/20	FOS	Continue to analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.00
05/14/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
05/14/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.30
05/14/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.80
05/14/20	MFR	Call with R. Collura, M. Rule (both AlixPartners) re: status of the intercompany and non-cash transfers of value report.	0.30
05/14/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	0.80
05/14/20	MFR	Review of workpapers supporting the intercompany and	2.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		non-cash transfers report and analyses.	
05/14/20	FOS	Compose email to J. Lowne and E. Liesman (all Purdue) re: payments and intercompany charges between Purdue and TXP.	0.40
05/14/20	FOS	Email to R. Collura and K. Shibuya (all AlixPartners) re: intercompany charges between Purdue and Mundipharma International Limited (USA) and Mundipharma International Technical Operations Limited.	0.20
05/14/20	FOS	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.40
05/14/20	FOS	Calls with J. Hecht, F. Silva (both AlixPartners) re: charges between Purdue and TXP for services.	0.40
05/14/20	FOS	Conference call with E. Liesman (Purdue), J. Hecht, F. Silva (both AlixPartners) re: charges between Purdue and TXP for services.	0.60
05/14/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	3.00
05/15/20	FOS	Analyze and reconcile SAP data re: shared services charges between Purdue and Rhodes entities.	2.00
05/15/20	FOS	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/15/20	FOS	Conference call with J. Lowne (Purdue) and M. Rule, F. Silva (both AlixPartners) re: outstanding information requests for draft intercompany and non-cash transfers report.	0.70
05/15/20	FOS	Conference call with M. Clarens, E. Kim, C. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: update on status of draft intercompany and non-cash transfers report.	0.90
05/15/20	FOS	Draft and edit report re: intercompany and non-cash	3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		transfers report.	
05/15/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.10
05/15/20	MFR	Calls with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.50
05/15/20	MFR	Conference call with J. Lowne (Purdue) and M. Rule, F. Silva (both AlixPartners) re: outstanding information requests for draft intercompany and non-cash transfers report.	0.70
05/15/20	MFR	Conference call with M. Clarens, E. Kim, C. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: update on status of draft intercompany and non-cash transfers report.	0.90
05/15/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.40
05/15/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	3.20
05/15/20	FOS	Continue to draft and edit report re: intercompany and non-cash transfers report.	2.00
05/15/20	SJC	Analysis of intercompany transfer related payments in SAP for sale of goods.	2.00
05/15/20	SJC	Analysis of intercompany payments in SAP related to Purdue Canada.	2.50
05/15/20	SJC	Analysis of OSR rent related payments in SAP.	1.00
05/15/20	SJC	Analysis of inter company payments in SAP related to Purdue Canada/Avrio.	1.00
05/15/20	SJC	Retrieve Rhodes intercompany payment support from SAP.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/15/20	KS	Update a report 1B re: transfer pricing.	1.60
05/15/20	JDH	Analysis of 2010 Bank statement.	2.70
05/15/20	JDH	Analysis of 2008 Distribution.	2.60
05/15/20	JDH	Review Report 1B	1.10
05/15/20	RC	Review various correspondence from TXP's counsel.	0.20
05/15/20	RC	Review additional sections of the intercompany and non-cash transfers of value report.	1.10
05/15/20	RC	Review documentation related to cash distributions.	0.40
05/15/20	RC	Conference call with M. Clarens, E. Kim, C. Kim, A. Whisenant (all Davis Polk), R. Collura, M. Rule, F. Silva (all AlixPartners) re: update on status of draft intercompany and non-cash transfers report.	0.90
05/15/20	RC	Review additional updates made to the intercompany and non-cash transfers of value report.	1.00
05/15/20	RC	Call with R. Collura, A. DePalma (AlixPartners) re: response to emails from TXP's counsel.	0.20
05/15/20	RC	Review responses from TXP counsel and prepare additional follow-up responses.	0.60
05/15/20	RC	Follow-up call with R. Collura, A. DePalma (both AlixPartners) re: additional responses to TXP's counsel.	0.40
05/15/20	RC	Review and comment on intercompany and non-cash transfers of value report.	1.40
05/15/20	RC	Review updated bank statement index.	0.10
05/15/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: response to emails from TXP's counsel.	0.20
05/15/20	ADD	Follow-up call with R. Collura, A. DePalma (both AlixPartners) re: additional responses to TXP's counsel.	0.40
05/15/20	ADD	Review responses to UCC tax requests provided by	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		Purdue's accounting tax/services provided.	
05/15/20	ADD	Update diligence request tracker for TXP services.	1.20
05/15/20	ADD	Draft responses to TXPs responsive materials explaining the status of outstanding requests.	0.90
05/16/20	RC	Review comments and updated intercompany and non-cash transfer of value report.	1.40
05/16/20	FOS	Perform quality control on draft report re: intercompany and non-cash transfers.	3.00
05/17/20	FOS	Perform quality control on draft report re: intercompany and non-cash transfers.	4.00
05/17/20	FOS	Continue quality control on draft report re: intercompany and non-cash transfers.	4.00
05/17/20	RC	Review updated draft of the intercompany and non-cash transfer report and provide comments to the team.	2.60
05/18/20	RC	Call with R. Collura, A. DePalma (AlixPartners) re: status of responses to requests made to TXP.	0.60
05/18/20	RC	Call with R. Collura, A. DePalma (AlixPartners) re: status of responses to UCC and Ad Hoc Committee's diligence requests.	0.20
05/18/20	RC	Review SAP information related to property taxes.	0.30
05/18/20	RC	Review documentation related to non-cash distributions.	0.70
05/18/20	RC	Review SAP information related to transactions with IACs.	0.80
05/18/20	RC	Review reconciliation to the schedules included in the MDL presentation.	0.80
05/18/20	RC	Review information related to property taxes.	0.80
05/18/20	RC	Review additional updates and comments related to the intercompany and non-cash transfers report.	1.30
05/18/20	RC	Review supporting documentation related to transactions	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/18/20	RC	with IACs.	
05/18/20	RC	Coordinate staffing for quality control review of the intercompany and non-cash transfers report.	0.20
05/18/20	RC	Review support documentation provided in response to requests for information related to the cash transfers of value report.	0.40
05/18/20	RC	Review SAP information related to payroll withholding taxes.	0.60
05/18/20	JDH	Review Report 1B.	3.20
05/18/20	JDH	Continue to Review Report 1B.	2.00
05/18/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: quality control of draft intercompany and non-cash transfers report.	0.20
05/18/20	FOS	Perform quality control re: draft intercompany and non-cash transfers report.	3.80
05/18/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.50
05/18/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.20
05/18/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: quality control of draft intercompany and non-cash transfers report.	0.20
05/18/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.30
05/18/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.10
05/18/20	SJC	Review of report 1B exhibits 1a-1p to underlying documents, accuracy, and internal consistency.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/18/20	SJC	Continue review of report 1B exhibits 1a-1p to underlying documents, accuracy, and internal consistency.	3.00
05/18/20	SJC	Further review of report 1B exhibits 1a-1p to underlying documents, accuracy, and internal consistency.	2.50
05/18/20	REO	Reconcile and consolidate excel support for international royalties analysis: quarterly royalties for Q1-Q2 2012.	1.40
05/18/20	REO	Continue to reconcile and consolidate excel support for international royalties analysis: quarterly royalties for Q1-Q2 2013.	1.00
05/18/20	REO	Continue to reconcile and consolidate excel support for international royalties analysis: quarterly royalties for Q3-Q4 2012.	1.20
05/18/20	REO	Reconcile and consolidate excel support for international royalties analysis: quarterly royalties for Q3-Q4 2013.	1.30
05/18/20	REO	Reconcile and consolidate excel support for international royalties analysis: quarterly royalties for Q1-Q2 2014.	1.50
05/18/20	REO	Continue to reconcile and consolidate excel support for international royalties analysis: quarterly royalties for Q3-Q4 2014.	1.40
05/18/20	ADD	Update diligence responses to incorporate comment from Purdue.	0.60
05/18/20	ADD	Review and update liabilities subject to compromise analysis.	2.80
05/18/20	ADD	Compile MOR bank balance and distribution MOR schedules.	0.60
05/18/20	ADD	Review (quality control) report 1B for constancy and compared charts to source data.	3.30
05/18/20	ADD	Call with R. Collura, A. DePalma (AlixPartners) re: status of responses to requests made to TXP.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/18/20	ADD	Call with R. Collura, A. DePalma (AlixPartners) re: status of responses to UCC and Ad Hoc Committee's diligence requests.	0.20
05/19/20	ADD	Review 1B report for third-party confidentiality.	2.50
05/19/20	SJC	Review of report 1B exhibits 1q, 1r, 4e, 4g, 4h, 4i, 4j, and 4k to underlying documents, accuracy, and internal consistency.	3.00
05/19/20	SJC	Continue review of report 1B exhibits 1q, 1r, 4e, 4g, 4h, 4i, 4j, and 4k to underlying documents, accuracy, and internal consistency.	3.30
05/19/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	3.20
05/19/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	1.70
05/19/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	2.60
05/19/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.80
05/19/20	FOS	Perform quality control re: draft intercompany and non-cash transfers report.	3.50
05/19/20	FOS	Compose email to M. Clarens, E. Kim, C. Kim, A. Whisenant (all Davis Polk) re: quality control of draft intercompany and non-cash transfers report.	0.20
05/19/20	JDH	Complete review of report 1B.	3.00
05/19/20	JDH	Further review of report 1B.	3.10
05/19/20	JDH	Review of distribution documentation for 2012.	1.90
05/19/20	RC	Review communications related to responses provided by TXP's counsel.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/19/20	RC	Review support documentation related to transactions with IACs.	0.80
05/19/20	RC	Review support documentation related to non-cash distributions.	1.20
05/19/20	RC	Review transactions detail related to loans to IACs.	1.10
05/19/20	RC	Review support documentation provided to the UCC and NCSG in connection with the cash transfers of value report.	0.50
05/19/20	RC	Review documentation provided by TXP in response to requests from the UCC.	0.60
05/20/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: the intercompany and non-cash transfers report.	0.20
05/20/20	RC	Review additional responses from TXP's counsel.	0.60
05/20/20	RC	Review and respond to questions from the UCC's advisors.	0.10
05/20/20	RC	Review additional data provided by TXP related to distribution requests.	0.80
05/20/20	RC	Review and comment on responses to requests made by the UCC's advisors.	0.30
05/20/20	RC	Review payments to the IACs and research available information in response to requests made by the UCC.	0.70
05/20/20	RC	Review and respond to questions from Davis Polk on status of TXP's responses to various requests.	0.20
05/20/20	RC	Perform review of information available in connection with responding to tax and payment requests by the UCC.	0.60
05/20/20	RC	Review status of UCC's diligence requests and provide comments.	0.40
05/20/20	RC	Review documentation related to the intercompany and non-cash transfer report.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/20/20	JDH	Review of bank statement documentation.	2.10
05/20/20	JDH	Distribution of 2010 Tax documentation.	4.00
05/20/20	JDH	Continue review of bank statement documentation.	2.00
05/20/20	FOS	Perform quality control re: draft intercompany and non-cash transfers report.	0.50
05/20/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.30
05/20/20	MFR	Review and analysis of intercompany accounts related to the intercompany and non-cash transfers report and supporting analyses.	2.10
05/20/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.60
05/20/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	1.90
05/20/20	SJC	Review of SAP documents for 2009 distributions.	3.50
05/20/20	SJC	Continue review of SAP documents for 2009 distributions.	3.50
05/20/20	ADD	Review 1B report for third-party confidentiality.	2.10
05/20/20	ADD	Review and compile diligence materials and responses to tax requests to discuss with Davis Polk.	2.60
05/20/20	ADD	Compile materials in response to diligence request to be sent to Davis Polk eDiscovery	0.80
05/20/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: the intercompany and non-cash transfers report.	0.20
05/20/20	ADD	Research parties provided by David Polk for third party relationships to identify potential confidentiality issues.	2.30
05/21/20	ADD	Compile materials in response to diligence request to be sent to Davis Polk eDiscovery.	0.60
05/21/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re:	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		responses to diligence requests.	
05/21/20	ADD	Review transactions in client's account system to understand account methodology and implications.	2.20
05/21/20	ADD	Review and compile diligence materials and responses to tax requests to discuss with Davis Polk.	1.80
05/21/20	ADD	Research entity relationships for potential redaction.	3.00
05/21/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.60
05/21/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.90
05/21/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.10
05/21/20	JDH	Distribution of 2008 tax documentation.	3.20
05/21/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to diligence requests.	0.60
05/21/20	RC	Review information provided by TXP in response to various diligence requests.	1.20
05/21/20	RC	Communicate with Davis Polk re: status of responses to the UCC's diligence requests.	0.20
05/21/20	RC	Review status of tax return and related information provided by TXP.	0.30
05/21/20	RC	Review documentation provided to the UCC in connection with the cash transfers of value report.	0.70
05/21/20	RC	Review documentation provided to the UCC in response to agreements with IACs.	0.40
05/21/20	RC	Review and provide comments related to the tax information request tracker.	0.40
05/22/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re:	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		responses to bank information diligence requests.	
05/22/20	RC	Review bank statement information requests from the UCC.	0.20
05/22/20	RC	Review additional updates to the intercompany and non-cash transfers of value report.	0.90
05/22/20	RC	Review updated responses to the UCC's request for tax related information.	0.40
05/22/20	JDH	Continue distribution of 2010 and 2008 ex-USdocumentation.	2.50
05/22/20	JDH	Distribution of 2010 and 2008 ex-USdocumentation.	2.80
05/22/20	MFR	Review of and revisions to the intercompany and non-cash transfers report and supporting analyses.	3.60
05/22/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	1.40
05/22/20	SJC	Review of lead sheets for 2009, 2011, 2013, 2015 and 2017 distribution testing for completeness, accuracy, and potential open items.	3.50
05/22/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: responses to bank information diligence requests.	0.20
05/26/20	ADD	Call with R. Collura and A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: responses to the UCC's tax related diligence requests.	0.40
05/26/20	SJC	Review of lead sheets for 2009, 2011, 2013, 2015 and 2017 distribution testing for completeness, accuracy, and potential open items.	3.00
05/26/20	SJC	Review of lead sheets for 2009, 2011, 2013, 2015 and 2017 distribution testing for completeness, accuracy, and potential open items (Continue).	3.00
05/26/20	SJC	Review of lead sheets for 2009, 2011, 2013, 2015 and	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		2017 distribution testing for completeness, accuracy, and potential open items (Continue).	
05/26/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.80
05/26/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	3.30
05/26/20	MFR	Call with R. Collura, M. Rule and F. Silva (AlixPartners) and M. Claren, E. Kim and A. Whisenant (Davis Polk) re: the intercompany and non-cash transfers of value report.	0.30
05/26/20	FOS	Call with R. Collura, M. Rule and F. Silva (AlixPartners) and M. Claren, E. Kim and A. Whisenant (Davis Polk) re: the intercompany and non-cash transfers of value report.	0.30
05/26/20	JDH	Documentation of 2008 non-tax distributions.	2.40
05/26/20	JDH	Continue documentation of 2008 non-tax distributions.	2.40
05/26/20	RC	Call with R. Collura, M. Rule and F. Silva (AlixPartners) and M. Claren, E. Kim and A. Whisenant (Davis Polk) re: the intercompany and non-cash transfers of value report.	0.30
05/26/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: discuss updates to the UCC's tax request tracker.	0.30
05/26/20	RC	Call with R. Collura and A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: responses to the UCC's tax related diligence requests.	0.40
05/26/20	RC	Review and comment on responses to the UCC's tax requests.	0.60
05/26/20	RC	Review information provided by TXP's counsel and update comments to tracking schedule.	0.90
05/27/20	JD	Meeting with J. DelConte, A. DePalma, S. Lemack (all AlixPartners) re: latest workstream updates and discuss next steps.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
05/27/20	RC	Review and provide comments re: updating TXP information response tracker.	0.40
05/27/20	RC	Review and comment on support documentation gathered in response to the UCC's tax requests.	0.70
05/27/20	RC	Review and comment on support documentation gathered in response to the UCC's request for information related to the IACs.	0.80
05/27/20	RC	Review additional updates to the intercompany and non-cash transfers of value report.	1.10
05/27/20	JDH	Review of 2014 bank statements.	3.80
05/27/20	JDH	Reviewing of 2012 bank statements.	2.30
05/27/20	JDH	Documentation of 2014 not-tax distributions.	2.10
05/27/20	SKL	Meeting with J. DelConte, A. DePalma, S. Lemack (all AlixPartners) re: latest workstream updates and discuss next steps.	0.60
05/27/20	MFR	Review of revisions to the intercompany and non-cash transfers report.	1.80
05/27/20	FOS	Perform quality review and edit draft report re: intercompany and non-cash transfers report.	2.10
05/27/20	FOS	Continue to perform quality review and edit draft report re: intercompany and non-cash transfers report.	2.00
05/27/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	3.30
05/27/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	3.60
05/27/20	ADD	In response to diligence request, research outstanding distribution and identify any supporting material in SAP.	2.40
05/27/20	ADD	Meeting with J. DelConte, A. DePalma, S. Lemack (all AlixPartners) re: latest workstream updates and discuss	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		next steps.	
05/28/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: status of responses received from TXP re: information requests.	0.50
05/28/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners) re: discuss responses to information provided by TXP's counsel.	0.40
05/28/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	2.80
05/28/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	3.60
05/28/20	FOS	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
05/28/20	MFR	Call with M. Rule, F. Silva (both AlixPartners) re: draft intercompany and non-cash transfers report.	0.20
05/28/20	MFR	Review of revisions to the intercompany and non-cash transfers report.	1.60
05/28/20	MFR	Review of revisions to the intercompany and non-cash transfers report.	0.80
05/28/20	JDH	Documentation of 2008 non-tax distributions.	3.90
05/28/20	JDH	Continuation of 2010 non tax distribution documentation.	1.10
05/28/20	RC	Call with R. Collura, A. DePalma (both AlixPartners) re: discuss responses to information provided by TXP's counsel.	0.40
05/28/20	RC	Review TXP diligence tracker and provide comments related to open items.	0.60
05/28/20	RC	Review intercompany and non-cash transfer report and additional comments provided.	1.20
05/28/20	RC	Review status of documentation gathered in response to	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		requests made by the UCC.	
05/28/20	RC	Review tax related documentation provided by TXP's counsel.	0.70
05/28/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) and C. Oluwole (Davis Polk) re: status of responses received from TXP re: information requests.	0.50
05/29/20	RC	Review and analysis of documentation provided by TXP in response to various requests for information.	0.70
05/29/20	RC	Review documentation gathered in response to requests from the UCC.	0.80
05/29/20	RC	Review SAP documentation gathered in response to tax requests made by the UCC.	1.10
05/29/20	MFR	Review of workpapers supporting the intercompany and non-cash transfers report and analyses.	2.50
05/29/20	MFR	Review of revisions to the intercompany and non-cash transfers report.	1.10
05/29/20	MFR	Quality control of the intercompany and non-cash transfers report and supporting analyses.	3.40
		Total	<u>674.80</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Roy Ellis Ochoa	8.40	420.00	3,528.00
Andrew D DePalma	38.70	515.00	19,930.50
Sam K Lemack	0.60	515.00	309.00
Sam J Canniff	117.60	645.00	75,852.00
Kyoko Shibuya	14.40	645.00	9,288.00
Fernando O Silva	103.90	645.00	67,015.50
Jon D Hecht	122.50	690.00	84,525.00
Mark F Rule	166.60	910.00	151,606.00
Jesse DelConte	5.40	950.00	5,130.00
Richard Collura	96.70	1,090.00	105,403.00
Total Hours & Fees	674.80		522,587.00

Exhibit B

Alix Partners, LLP

Summary and Detailed Description of AlixPartners' Expenses

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Expense

Client/Matter # 012589.00150

Date	Disbursement Description	Amount
04/02/20	Conference Calls Vendor: Vodafone Ryan Sublett	16.60
04/02/20	Conference Calls Vendor: Vodafone Jesse Delconte	23.86
04/04/20	Conference Calls Vendor: Vodafone Ryan Sublett	32.88
04/04/20	Conference Calls Vendor: Vodafone Ryan Sublett	1.85
04/16/20	Conference Calls Vendor: Vodafone Jesse Delconte	33.82
04/26/20	Airfare Samuel Lemack 03.01.20 DFW - LGA	(5.60)
04/28/20	Conference Calls Vendor: Vodafone Ryan Sublett	8.42
05/20/20	Other Mitratech Holdings Inc. / Collaborati service for Purdue Pharma	10,000.00
Total Disbursements		10,111.83

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2125046-2

Re: Expense

Client/Matter # 012589.00150

Disbursement Recap:

Description	Amount
Airfare	(5.60)
Other	10,117.43
Total Disbursements	<u>10,111.83</u>